



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 451/02, 451/04, 451/06, A01N 43/90	A1	(11) International Publication Number: WO 98/25923 (43) International Publication Date: 18 June 1998 (18.06.98)
(21) International Application Number: PCT/GB97/02986 (22) International Filing Date: 30 October 1997 (30.10.97) (30) Priority Data: 9624611.1 26 November 1996 (26.11.96) GB (71) Applicant (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): URCH, Christopher, John [GB/GB]; Zeneca Agrochemicals, Jealott's Hill Research Station, Bracknell, Berkshire RG42 6ET (GB). LEWIS, Terence [GB/GB]; Zeneca Agrochemicals, Jealott's Hill Research Station, Bracknell, Berkshire RG42 6ET (GB). SUNLEY, Raymond, Leo [GB/GB]; Zeneca Agrochemicals, Jealott's Hill Research Station, Bracknell, Berkshire RG42 6ET (GB). SALMON, Roger [GB/GB]; Zeneca Agrochemicals, Jealott's Hill Research Station, Bracknell, Berkshire RG42 6ET (GB). GODFREY, Christopher, Richard, Ayles [GB/GB]; Zeneca Agrochemicals, Jealott's Hill Research Station, Bracknell, Berkshire RG42 6ET (GB). BRIGHTWELL, Christopher, Ian [GB/GB]; Zeneca Agro-		chemicals, Jealott's Hill Research Station, Bracknell, Berkshire RG42 6ET (GB). (74) Agents: TIERNEY, Francis, John et al.; Zeneca Agrochemicals, Intellectual Property Dept., Jealott's Hill Research Station, P.O. Box 3538, Bracknell, Berkshire RG42 6YA (GB). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INSECTICIDES (57) Abstract <p>A compound of formula (I) wherein Ar is optionally substituted phenyl or optionally substituted 5- or 6-membered heterocyclic ring containing from 1 to 3 heteroatoms individually selected from nitrogen, oxygen and sulfur atoms, and at least one unsaturation (double bond) between adjacent atoms in the ring, said heterocyclic ring being optionally fused to a benzene ring, wherein the substituents, if present, are selected from halogen atoms, cyano, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkenyl, alkylthio and alkyl amino groups; R represents hydrogen or cyano or a group selected from alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, aralkenyl, alkynyl, alkoxycarbonyl, alkanesulfonyl, arenesulfonyl, alkenyloxycarbonyl, aralkyloxycarbonyl, aryloxycarbonyl, heterocyclalkyl, carbamyl, dithiocarbonyl or XR³ (where X represents oxygen or a group NR⁴), provided that when R is alkenyl, aralkenyl or alkynyl said group does not have an unsaturated carbon atom bonding directly to the ring nitrogen of formula (I); R³ and R⁴ are, independently, hydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, aralkenyl, alkynyl, heterocyclalkyl, alkoxycarbonyl or carboxylic acyl; alkyl moieties of R, R³ and R⁴ comprise from 1 to 15 carbon atoms, and are optionally substituted with one or more substituents selected from halogen, cyano, carbonyl, carboxylic acyl, carbamyl, alkoxycarbonyl, alkoxy, alkylenedioxy, hydroxy, nitro, amino, acylamino, imidate and phosphonate groups; aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, aralkenyl, alkynyl, alkoxycarbonyl, alkanesulfonyl, arenesulfonyl, alkenyloxycarbonyl, aralkyloxycarbonyl, aryloxycarbonyl, heterocyclalkyl, carbamyl or dithiocarbonyl moieties of R, R³ and R⁴ comprise from 1 to 15 carbon atoms, and are optionally substituted with one or more substituents selected from, halogen, cyano, carbonyl, carboxylic acyl, carbamyl, alkoxycarbonyl, alkoxy, alkylenedioxy, hydroxy, nitro, haloalkyl, alkyl, amino, acylamino, imidate and phosphonate groups; R¹ represents hydrogen, hydroxy, alkyl, alkoxy, amino, nitro, isocyanato, acylamino, hydroxyalkyl, optionally substituted heteroaryl, alkoxyalkyl, haloalkyl, haloalkoxyalkyl, aralkyloxyalkyl, acyloxyalkyl, amidoximido, sulfonyloxyalkyl, aminoalkyl, alkoxycarbonylamino, acylaminoalkyl, cyanoalkyl, imino, formyl, acyl or carboxylic acid or an ester or amide thereof, or alkenyl or alkynyl either of which is optionally substituted by halogen, alkoxy, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl or cyano; or an acid addition salt, quaternary ammonium salt or N-oxide derived therefrom; an insecticidal, acaricidal or nematocidal composition comprising a compound of formula (I) and a suitable carrier or diluent therefor; a method of combating and controlling insect, acarine or nematode pests at a locus which comprises treating the pests or the locus of the pests with an effective amount of a compound of formula (I) or a composition as hereinbefore described.</p> <div style="text-align: center;"> <p style="text-align: right;">(I)</p> </div>		

53

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China			PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INSECTICIDES

This invention relates to novel bicyclic amine derivatives, to processes for preparing them, to insecticidal compositions comprising and to methods of using them to combat and control insect pests.

5 The invention provides a compound of formula (I):



wherein Ar is optionally substituted phenyl or optionally substituted 5-or 6-membered heterocyclic ring containing from 1 to 3 heteroatoms individually selected from nitrogen, oxygen and sulfur atoms, and at least one unsaturation (double bond) between adjacent atoms in the ring, said heterocyclic ring being optionally fused to a benzene ring, wherein the substituents, if present, are selected from halogen atoms, cyano, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkenyl, alkylthio and alkyl amino groups; R represents hydrogen or cyano or a group selected from alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, aralkenyl, alkynyl, alkoxycarbonyl, alkanesulfonyl, arenesulfonyl, alkenyloxycarbonyl, aralkyloxycarbonyl, aryloxycarbonyl, heterocyclalkyl, carbamyl, dithiocarboxyl or XR^3 (where X represents oxygen or a group NR^4), provided that when R is alkenyl, aralkenyl or alkynyl said group does not have an unsaturated carbon atom bonding directly to the ring nitrogen of formula (I); R^3 and R^4 are, independently, hydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, aralkenyl, alkynyl, heterocyclalkyl, alkoxycarbonyl or carboxylic acyl; alkyl moieties of R, R^3 and R^4 comprise from 1 to 15 carbon atoms, and are optionally substituted with one or more substituents selected from halogen, cyano, carboxyl, carboxylic acyl, carbamyl, alkoxycarbonyl, alkoxy, alkylenedioxy, hydroxy, nitro, amino, acylamino, imidate and phosphonato groups; aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, aralkenyl, alkynyl, alkoxycarbonyl, alkanesulfonyl, arenesulfonyl, alkenyloxycarbonyl, aralkyloxycarbonyl, aryloxycarbonyl, heterocyclalkyl, carbamyl or dithiocarboxyl moieties of R, R^3 and R^4 comprise from 1 to 15 carbon atoms, and are optionally substituted with one or more substituents selected from, halogen, cyano, carboxyl,

carboxylic acyl, carbamyl, alkoxycarbonyl, alkoxy, alkylenedioxy, hydroxy, nitro, haloalkyl, alkyl, amino, acylamino, imidate and phosphonato groups; R¹ represents hydrogen, hydroxy, alkyl, alkoxy, amino, nitro, isocyanato, acylamino, hydroxyalkyl, optionally substituted heteroaryl, alkoxyalkyl, haloalkyl, halohydroxyalkyl, aralkyloxyalkyl, acyloxyalkyl, 5 amidoximido, sulfonyloxyalkyl, aminoalkyl, alkoxycarbonylamino, acylaminoalkyl, cyanoalkyl, imino, formyl, acyl or carboxylic acid or an ester or amide thereof, or alkenyl or alkynyl either of which is optionally substituted by halogen, alkoxy, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl or cyano; or an acid addition salt, quaternary ammonium salt or N-oxide derived therefrom.

10 It will be appreciated that the bicyclic amine compounds of formula (I) are capable of existing in more than one isomeric form since the groups Ar and R¹ may be positioned in either an exo or endo relationship, and the present invention embraces within its scope both exo and endo forms and mixtures thereof in all proportions and also any further isomeric variants arising from cis and trans substitution patterns or chiral centres present in either of 15 Ar, R or R¹.

Examples of 5- and 6-membered heterocyclic ring systems represented by Ar include those based on pyridine, pyrazine, pyridazine, pirimidine, pyrrole, pyrazole, imidazole, 1,2,3- and 1,2,4-triazoles, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, 1,2,3- and 1,3,4-oxadiazoles, and 1,2,3- and 1,3,4-thiadiazoles, and partially reduced containing one 20 double bond derived from these, as well as those based on oxathiole, dioxole, and dithiole rings containing one double bond. Preferably Ar represents a halo-substituted phenyl, pyridyl or diazinyl group.

When Ar is a 5- or 6- membered hererocyclic ring fused to a benzene ring then it is preferably benzoxazole, indole, benzofuran, benzothiophen or benzimidazole.

25 Halogen includes fluorine, chlorine, bromine and iodine.

Alkyl moieties preferably contain from 1 to 6, more preferably from 1 to 4, carbon atoms. They can be in the form of straight or branched chains, for example methyl, ethyl, n- or iso-propyl, or n-, sec-, iso- or tert-butyl.

Haloalkyl is preferably C₁₋₆ haloalkyl, especially fluoroalkyl (for example 30 trifluoromethyl, 2,2,2-trifluoroethyl or 2,2-difluoroethyl) or chloroalkyl. For R, haloalkyl is

preferably C₂₋₆ haloalkyl wherein there is no halogen on the α -carbon (for example 2,2,2-trifluoroethyl or 2,2-difluoroethyl).

Alkenyl and alkynyl moieties of R¹ and substituents of Ar preferably contain from 2 to 6, more preferably from 2 to 4, carbon atoms. They can be in the form of straight or
5 branched chains, and, where appropriate, the alkenyl moieties can be of either (E)- or (Z)-configuration. Examples are vinyl, allyl and propargyl.

Aryl includes naphthyl but is preferably phenyl.

Heteroaryl includes 5- and 6-membered aromatic rings containing one, two, three or four heteroatoms selected from the list comprising oxygen, sulphur and nitrogen and can be
10 fused to benzenoid ring systems. Examples of heteroaryl are pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl (1,2,3-, 1,2,4- and 1,3,5-), furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl (1,2,3- and 1,2,4-), tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolinyl, isoindolinyl, benzofuranyl, benzothienyl and benzimidazolyl.

15 The heterocyclyl part of heterocyclylalkyl is a ring containing one or two heteroatoms selected from the list comprising oxygen, sulphur and nitrogen. Examples are piperidine, piperazine, pyrrolidine, tetrahydrofuran, morpholine, thietane, pyridine or thiazole.

The alkylenedioxy group is a substituent for a ring and is especially C₁₋₄ alkylenedioxy. Alkylenedioxy groups are optionally substituted with halogen (especially
20 fluorine) and are, for example, methylenedioxy (OCH₂O) or difluoromethylenedioxy (OCF₂O).


Suitable acid addition salts include those with an inorganic acid such as hydrochloric, hydrobromic, sulfuric, nitric and phosphoric acids, or an organic carboxylic acid such as
25 oxalic, tartaric, lactic, butyric, toluic, hexanoic and phthalic acids, or sulphonic acids such as methane, benzene and toluene sulphonic acids. Other examples of organic carboxylic acids include haloacids such as trifluoroacetic acid.

In one particular aspect the present invention provides a compound of formula (I), wherein Ar is optionally substituted phenyl or optionally substituted 5- or 6-membered
heterocyclic ring containing from 1 to 3 heteroatoms individually selected from nitrogen,
30 oxygen and sulfur atoms, and at least one unsaturation (double bond) between adjacent atoms in the ring, said heterocyclic ring being optionally fused to a benzene ring, wherein the

substituents, if present, are selected from halogen atoms, cyano, alkyl (especially C₁₋₄ alkyl), alkenyl (especially C₂₋₄ alkenyl), alkynyl (especially C₂₋₄ alkynyl), alkoxy (especially C₁₋₄ alkoxy), haloalkyl (especially C₁₋₄ haloalkyl), haloalkenyl (especially C₂₋₄ haloalkenyl), alkylthio (especially C₁₋₄ alkylthio), and alkyl amino (especially mono- or di- (C₁₋₄ alkyl)amino, such as mono- or di- (C₁₋₃ alkyl)amino) groups; R represents hydrogen or cyano or a group selected from alkyl (especially C₁₋₄ alkyl), aryl (especially phenyl), heteroaryl (especially pyridinyl or pyrimidinyl), aralkyl (especially aryl(C₁₋₄)alkyl, such as phenyl(C₁₋₄)alkyl), heteroarylalkyl (especially heteroaryl(C₁₋₄)alkyl, such as pyridinyl(C₁₋₄)alkyl or pyrimidinyl(C₁₋₄)alkyl), alkenyl (especially C₃₋₄ alkenyl), aralkenyl (especially aryl(C₃₋₄)alkenyl, such as phenyl(C₃₋₄)alkenyl), alkynyl (especially C₃₋₄ alkynyl), alkoxycarbonyl (especially C₁₋₄ alkoxycarbonyl), alkanesulfonyl (especially C₁₋₄ alkylsulfonyl), arenesulfonyl (especially phenylsulfonyl), alkenyloxycarbonyl (especially C₃₋₄ alkenyloxycarbonyl), aralkyloxycarbonyl (especially phenyl(C₁₋₄)alkoxycarbonyl), aryloxycarbonyl (especially phenoxycarbonyl), heterocyclalkyl (especially heterocycl(C₁₋₄)alkyl, such as piperidinyl(C₁₋₄)alkyl), carbamyl (H₂NC(O)), dithiocarboxyl or XR³ (where X represents oxygen or a group NR⁴), provided that when R is alkenyl, aralkenyl or alkynyl said group does not have an unsaturated carbon atom bonding directly to the ring nitrogen of formula (I); R³ and R⁴ are, independently, hydrogen, alkyl (especially C₁₋₄ alkyl), aryl (especially phenyl), heteroaryl (especially pyridinyl or pyrimidinyl), aralkyl (especially aryl(C₁₋₄)alkyl, such as phenyl(C₁₋₄)alkyl), heteroarylalkyl (especially heteroaryl(C₁₋₄)alkyl, such as pyridinyl(C₁₋₄)alkyl or pyrimidinyl(C₁₋₄)alkyl), alkenyl (especially C₂₋₄ alkenyl), aralkenyl (especially aryl(C₂₋₄)alkenyl, such as phenyl(C₂₋₄)alkenyl), alkynyl (especially C₂₋₄ alkynyl), heterocyclalkyl (especially heterocycl(C₁₋₄)alkyl, such as piperidinyl(C₁₋₄)alkyl), alkoxycarbonyl (especially C₁₋₄ alkoxycarbonyl) or carboxylic acyl (especially C₁₋₄ alkylcarbonyloxy); alkyl moieties of R, R³ and R⁴ comprise from 1 to 15 carbon atoms, and are optionally substituted with one or more substituents selected from halogen, cyano, carboxyl (HOC(O)), carboxylic acyl (especially C₁₋₄ alkylcarbonyloxy), carbamyl (H₂NC(O)), alkoxycarbonyl (especially C₁₋₄ alkoxycarbonyl), alkoxy (especially C₁₋₄ alkoxy), alkylenedioxy (especially C₁₋₄ alkylenedioxy), hydroxy, nitro, amino, acylamino (especially C₁₋₄ alkylcarbonylamino), imidate (C₁₋₄ alkyl[C(O)NHC(O)]) and phosphonato (OP(OH)₂) groups; aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, aralkenyl, alkynyl, alkoxycarbonyl,

alkanesulfonyl, arenesulfonyl, alkenyloxycarbonyl, aralkyloxycarbonyl, aryloxycarbonyl, heterocyclalkyl, carbamyl, dithiocarboxyl moieties of R, R³ and R⁴ comprise from 1 to 15 carbon atoms, and are optionally substituted with one or more substituents selected from, halogen, cyano, carboxyl (HOC(O)), carboxylic acyl (especially C₁₋₄ alkylcarbonyloxy), carbamyl (H₂NC(O)), alkoxycarbonyl (especially C₁₋₄ alkoxycarbonyl), alkoxy (especially C₁₋₄ alkoxy), alkylenedioxy (especially C₁₋₄ alkylenedioxy), hydroxy, nitro, haloalkyl (especially C₁₋₄ haloalkyl), alkyl (especially C₁₋₄ alkyl), amino, acylamino (especially C₁₋₄ alkylcarbonylamino), imidate (C₁₋₄ alkyl[C(O)NHC(O)]) and phosphonato (OP(OH)₂) groups; R¹ is hydrogen, hydroxy, alkyl (especially C₁₋₄ alkyl), alkoxy (especially C₁₋₄ alkoxy), amino (especially unsubstituted, mono- or di-(C₁₋₄)alkylamino or amino substituted with a formyl group), nitro, isocyanato, acylamino (especially C₁₋₄ alkylcarbonylamino or phenylcarbonylamino), hydroxyalkyl (especially monohydroxy(C₁₋₄)alkyl), optionally substituted heteroaryl (especially tetrazole, oxadiazole, pyridinyl or pyrimidinyl optionally substituted by halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy or C₁₋₄ haloalkoxy), alkoxyalkyl (especially C₁₋₄ alkoxy(C₁₋₄)alkyl), haloalkyl (especially C₁₋₄ haloalkyl), halohydroxyalkyl (especially C₁₋₄ halohydroxyalkyl, such as 2-hydroxy-1,1-difluoroethyl), aralkyloxyalkyl (especially phenyl(C₁₋₄)alkoxy(C₁₋₄)alkyl), acyloxyalkyl (especially C₁₋₄ alkylcarbonyloxy(C₁₋₄)alkyl), amidoximido (C(NH₂)NOH), sulfonyloxyalkyl (especially sulfonyloxy(C₁₋₄)alkyl), aminoalkyl (especially amino(C₁₋₄)alkyl), alkoxycarbonylamino (especially C₁₋₄ alkoxycarbonylamino), acylaminoalkyl (especially C₁₋₄ alkylcarbonylamino(C₁₋₄)alkyl or phenylcarbonylamino(C₁₋₄)alkyl), cyanoalkyl (especially C₁₋₄ cyanoalkyl), imino (especially hydroxyimino (HON=CH) or C₁₋₄ alkoxyimino), formyl, acyl (especially C₁₋₄ alkylcarbonyl) or carboxylic acid or an ester (especially a C₁₋₄ alkyl ester) or amide (especially an unsubstituted or an N,N-di(C₁₋₄)alkyl amide) thereof, or alkenyl (especially C₂₋₄ alkenyl) or alkynyl (especially C₂₋₄ alkynyl) either of which is optionally substituted by halogen, alkoxy (especially C₁₋₄ alkoxy), cycloalkyl (especially C₃₋₇ cycloalkyl, such as cyclopropyl or cyclohexyl), optionally substituted aryl (especially phenyl optionally substituted by halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy or C₁₋₄ haloalkoxy), optionally substituted heteroaryl (especially pyridinyl or pyrimidinyl optionally substituted by halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy or C₁₋₄ haloalkoxy) or cyano; or an acid addition salt, quaternary ammonium salt or N-oxide derived therefrom.

In a further aspect the present invention provides a compound of formula (Ia):



wherein A represents dimethylene; Ar represents an optionally substituted phenyl or 5- or 6-membered heterocyclic ring system containing from 1 to 3 heteroatoms individually selected from nitrogen, oxygen and sulfur atoms, and at least one unsaturation (double bond) between adjacent atoms in the ring, wherein the substituents, if present, are selected from halogen atoms, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkenyl, alkylthio and alkyl amino groups, any of which groups contain up to six carbon, and wherein R represents hydrogen or cyano or a group selected from alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, aralkenyl, alkynyl, alkoxycarbonyl, alkanesulfonyl, arenesulfonyl, alkanyloxycarbonyl, aralkyloxycarbonyl, aryloxycarbonyl, heterocyclalkyl, carbamyl or dithiocarboxyl groups, said groups comprising from 1 to 15 carbon atoms, said groups being optionally substituted with one or more substituents selected from, halogen, cyano, carboxyl, carboxylic acyl, carbamyl, alkoxycarbonyl, alkoxy, alkylendioxy, hydroxy, nitro, haloalkyl, alkyl, amino, acylamino, imidate and phosphonato groups; R¹ represents hydroxy, or a group selected from alkoxy, amino, acylamino, hydroxyalkyl, alkoxyalkyl, haloalkyl, halohydroxyalkyl, aralkyloxyalkyl, acyloxyalkyl, sulfonyloxyalkyl, aminoalkyl, acylaminoalkyl, cyanoalkyl, formyl, acyl, carboxylic acid and esters and amides thereof, alkenyl or alkynyl optionally substituted by halogen, alkoxy, aryl, heteroaryl or cyano; and acid addition salts and quaternary ammonium salts and N-oxides derived therefrom.

In a still further aspect the present invention provides a compound of formula (I), wherein Ar is pyridinyl (especially a pyridin-3-yl) optionally substituted by halogen (especially monosubstituted with chlorine or bromine), or phenyl optionally substituted by halogen (especially fluorine).

In another aspect the present invention provides a compound of formula (I), wherein Ar is phenyl, pyridinyl, pyridazinyl or pyrazinyl, all being optionally substituted with halogen (especially fluorine, chlorine or bromine), C₁₋₄ alkyl (especially methyl), C₁₋₄ alkoxy (especially methoxy), C₂₋₄ alkenyl, C₂₋₄ alkynyl or cyano.

In a further aspect the present invention provides a compound of formula (I) wherein R is C₁₋₄ alkyl (optionally substituted with cyano, CO₂(C₁₋₄ alkyl) or phenyl (itself optionally substituted with halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl or C₁₋₄ haloalkoxy)), C₂₋₄ haloalkyl (the α-carbon being unsubstituted), C₃₋₄ alkenyl or C₃₋₄ alkynyl; provided that when
 5 R is alkenyl or alkynyl said group does not have an unsaturated carbon atom bonding directly to the ring nitrogen of formula (I).

In yet another aspect the present invention provides a compound of formula (I), wherein R is C₁₋₄ alkyl (especially methyl), C₂₋₄ haloalkyl (the α-carbon being unsubstituted, especially C₂₋₄ fluoroalkyl, for example CH₂CF₃ or CH₂CF₂H) or C₁₋₄ alkoxycarbonyl (such
 10 as CH₃CH₂OC(O) or (CH₃)₃COC(O)).

In a further aspect the present invention provides a compound of formula (I), wherein R¹ is alkyl (especially C₁₋₄ alkyl), amino (especially mono- or di-(C₁₋₄)alkylamino), nitro, isocyanato, hydroxyalkyl (especially monohydroxy(C₁₋₄)alkyl), alkoxyalkyl (especially C₁₋₄ alkoxy(C₁₋₄)alkyl), haloalkyl (especially C₁₋₄ haloalkyl), halohydroxyalkyl (especially C₁₋₄
 15 halohydroxyalkyl, such as 2-hydroxy-1,1-difluoroethyl), aralkyloxyalkyl (especially phenyl(C₁₋₄)alkoxy(C₁₋₄)alkyl), acyloxyalkyl (especially C₁₋₄ alkylcarbonyloxy(C₁₋₄)alkyl), alkoxycarbonylamino (especially C₁₋₄ alkoxycarbonylamino), acylaminoalkyl (especially C₁₋₄ alkylcarbonylamino(C₁₋₄)alkyl or phenylcarbonylamino(C₁₋₄)alkyl), cyanoalkyl (especially C₁₋₄ cyanoalkyl), acyl (especially C₁₋₄ alkylcarbonyl) or carboxylic acid or an ester (especially
 20 a C₁₋₄ alkyl ester) thereof, or alkenyl (especially C₂₋₄ alkenyl) or alkynyl (especially C₂₋₄ alkynyl) either of which is optionally substituted by halogen, alkoxy (especially C₁₋₄ alkoxy), cycloalkyl (especially C₃₋₇ cycloalkyl, such as cyclopropyl or cyclohexyl), optionally substituted aryl (especially phenyl optionally substituted by halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy or C₁₋₄ haloalkoxy), optionally substituted heteroaryl (especially
 25 pyridinyl or pyrimidinyl optionally substituted by halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy or C₁₋₄ haloalkoxy) or cyano.

In a still further aspect the present invention provides a compound of formula (I), wherein R¹ is C₂₋₄ alkenyl (especially vinyl) or C₂₋₄ alkynyl (especially ethynyl) either of which is optionally substituted by halogen, alkoxy (especially C₁₋₄ alkoxy), cycloalkyl
 30 (especially C₃₋₇ cycloalkyl, such as cyclopropyl or cyclohexyl), phenyl (optionally substituted by halogen), pyridinyl (optionally substituted by halogen) or cyano.

Specific compounds of formula (I) are presented in Table I below.

TABLE I

Compound No.	Ar	R	R ¹
1	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CH(O)
2	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CH=CCl ₂
3	5-Cl-pyridin-3-yl	CH ₂ CF ₃	C≡CH
4	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CH ₂ OH
5	5-Cl-pyridin-3-yl	CH ₂ CF ₃	C≡CCl
6	5-Cl-pyridin-3-yl	CH ₂ CF ₃	H
7	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CO ₂ H
8	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CO ₂ CH ₃
9	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CH=NOH
10	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CH=NOCH ₃
11	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CH=C(CN) ₂
12	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CHF ₂
13	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CF ₃
14	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CH=CH ₂
15	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CH=CH(cyclopropyl)
16	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CH=CHOCH ₃
17	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CH=CHCl (<u>E</u>)
18	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CH=CHCl (<u>Z</u>)
19	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CH=CH(C ₆ H ₅)
20	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CH=CHCN (<u>E</u>)
21	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CH ₂ OCH ₃
22	5-Cl-pyridin-3-yl	CH ₂ CF ₃	C≡C(pyridin-3-yl)
23	5-Cl-pyridin-3-yl	CH ₂ CF ₃	C≡C(4-F-C ₆ H ₄)
24	5-Cl-pyridin-3-yl	CH ₂ CF ₃	C≡C(pyridin-2-yl)
25	5-Cl-pyridin-3-yl	CH ₂ CF ₃	CH ₂ OC(O)C(CH ₃) ₃
26	3,5-F ₂ -C ₆ H ₃	CH ₃	CH ₂ NHC(O)CH ₃
27	3,5-F ₂ -C ₆ H ₃	CH ₃	CH ₂ NH ₂

28	3,5-F ₂ -C ₆ H ₃	CH ₃	CH ₂ NHC(O)(C ₆ H ₅)
29	3,5-F ₂ -C ₆ H ₃	CH ₃	NHC(O)OCH ₃
30	pyridin-3-yl	CH ₃	OCH ₃
31	6-Cl-pyridin-3-yl	CO ₂ C(CH ₃) ₃	OCH ₃
32	6-Cl-pyridin-3-yl	CH ₃	OCH ₃
33	pyridin-3-yl	CO ₂ C(CH ₃) ₃	OCH ₃
34	5-Cl-pyridin-3-yl	CH ₂ CF ₃	tetrazol-5-yl
35	5-Cl-pyridin-3-yl	CH ₂ CF ₃	5-CH ₃ -1,2,4-oxadiazol-3-yl
36	5-Cl-pyridin-3-yl	CH ₂ CF ₃	C(NH ₂)=NOH
37	5-Cl-pyridin-3-yl	CO ₂ CH ₂ CH ₃	NH ₂
38	5-Cl-pyridin-3-yl	CO ₂ CH ₂ CH ₃	CONH ₂
39	5-Cl-pyridin-3-yl	CO ₂ CH ₂ CH ₃	NHCHO
40	5-Cl-pyridin-3-yl	CO ₂ CH ₂ CH ₃	*N≡C
41	5-Cl-pyridin-3-yl	CO ₂ CH ₂ CH ₃	NO ₂
42	5-Cl-pyridin-3-yl-N-oxide	CO ₂ CH ₂ CH ₃	NO ₂
43	3,5-F ₂ -C ₆ H ₃	CO ₂ C(CH ₃) ₃	OH
44	5-Cl-pyridin-3-yl	CH ₂ CH=CH ₂	CH=CH ₂
45	5-CN-pyridin-3-yl	CH ₂ CH=CH	CH=CH ₂
46	5-Br-pyridin-3-yl	CH ₂ CH≡CCH ₃	CH=CH ₂
47	5-CH ₃ O-pyridin-3-yl	CH ₂ CHF ₂	CH=CH ₂
48	5-acetylenyl-pyridin-3-yl	CH ₂ CO ₂ CH ₃	CH=CH ₂
49	6-Cl-pyrazin-2-yl	CH(CH ₃)CO ₂ CH ₃	CH=CH ₂
50	6-CH ₃ O-pyrazin-2-yl	CO ₂ CH ₃	CH=CH ₂
51	5-Cl-pyridin-3-yl	CH ₂ CN	CH=CH ₂
52	5-Cl-pyridin-3-yl	CH ₂ CH ₂ CN	CH=CH ₂
53	5-Cl-pyridin-3-yl	CH ₂ C ₆ H ₅	CH=CH ₂
54	5-Cl-pyridin-3-yl	CH ₂ CH ₂ CF ₃	CH=CH ₂
55	5-Cl-pyridin-3-yl	CH ₂ CH(CH ₃) ₂	CH=CH ₂
56	5-Cl-pyridin-3-yl	H	CH=CH ₂

The preparation of the compounds of formula (I) may be accomplished by use of one or more of the synthetic techniques described below and further illustrated in the Examples.

The compounds of formula (I) can be prepared from compounds of formula (II) by reacting the compounds of formula (II) in ways described in the literature to convert a cyano group to an R¹ group or replace a cyano group with an R¹ group.

Compounds of formula (II) can also be prepared by treating compounds of formula (VI) with a suitable base, such as lithium diisopropylamide (LDA), and reacting the product so formed with a halide ArHal, wherein Hal is a halogen atom.

Compounds of formula (VI) can be prepared by treating 3-cyano-8-azabicyclo[3.2.1]octane (VII) with a suitable base, such as potassium carbonate, in the presence of a halide RL', wherein L' is a leaving group (especially halogen or triflate).

3-Cyano-8-azabicyclo[3.2.1]octane (VII) can be prepared by demethylating 3-cyano-8-methyl-8-azabicyclo[3.2.1]octane (IV) by, for example, treating them with a chloroformate ester (such as vinyl chloroformate) to produce a carbamate, and subjecting the product so formed to acid hydrolysis.

Alternatively, compounds of formula (VI) can be prepared by treating compounds of formula (VIII) with tosylmethyl isocyanide in the presence of a suitable base, such as potassium ethoxide.

Compounds of formula (VIII) can be prepared by the Robinson tropinone synthesis, see, for instance, J. Chem. Soc., (1917) 111, 762. Alternatively, compounds of formula (VIII) can be prepared by reacting cyclohepta-2,6-dienone (XI) with an amine, RNH₂, as described in, for example, Tetrahedron, (1973) 155, Bull. Chem. Chem. Soc. Jpn., (1971) 44, 1708 or J. Org. Chem., (1971) 36, 1718.

The compounds of formula (I) wherein R is methyl, can be prepared from compounds of formula (III) by reacting the compounds of formula (III) in ways described in the literature to convert a cyano group to an R¹ group or replace a cyano group with an R¹ group.

Compounds of formula (III) can be prepared by treating 3-cyano-8-methyl-8-azabicyclo[3.2.1]octane (IV) with a suitable base, such as lithium diisopropylamide (LDA), and reacting the product so formed with a halide ArHal, wherein Hal is a halogen atom.

3-Cyano-8-methyl-8-azabicyclo[3.2.1]octane (IV) can be prepared by treating tropinone (V) with tosylmethyl isocyanide in the presence of a suitable base, such as

potassium ethoxide. Alternatively, 3-cyano-8-methyl-8-azabicyclo[3.2.1]octane (IV) can be prepared by treating tropine (X) with thionyl chloride to give 3-chloro-8-methyl-8-azabicyclo[3.2.1]octane (XII) and reacting (XII) with cyanide as described in J. Am. Chem. Soc., (1958) 80, 4677.

- 5 The compounds of formula (IX) (that is compounds of formula (I) wherein R¹ is hydroxy) can be prepared by reacting compounds of formula (VIII) with a product obtainable by treating a compound of formula ArHal (wherein Hal is a halogen) with a suitable lithium species (such as *n*-butyl lithium).

- 10 The hydroxy group present in the compounds of formula (IX) can be further reacted by methods known in the art to prepare other compounds of formula (I).

In further aspects the present invention provides processes for preparing compounds of formula (I), as hereinbefore described.

- 15 In a further aspect the invention provides a method of combating insect and like pests at a locus by applying to the locus or the pests an insecticidally effective amount of an insecticidal composition comprising a compound of formula (I) or an acid addition salt, quaternary ammonium salt or *N*-oxide derived therefrom.

- 20 The compounds of formula (I) can be used to combat and control infestations of insect pests such as Lepidoptera, Diptera, Homoptera and Coleoptera (including *Diabrotica* i.e. corn rootworms) and also other invertebrate pests, for example, acarine pests. The insect and acarine pests which may be combated and controlled by the use of the invention compounds include those pests associated with agriculture (which term includes the growing of crops for food and fibre products), horticulture and animal husbandry, forestry, the storage of products of vegetable origin, such as fruit, grain and timber, and also those pests associated with the transmission of diseases of man and animals. Examples of insect and
- 25 acarine pest species which may be controlled by the compounds of formula (I) include: *Myzus persicae* (aphid), *Aphis gossypii* (aphid), *Aphis fabae* (aphid), *Aedes aegypti* (mosquito), *Anopheles* spp. (mosquitos), *Culex* spp. (mosquitos), *Dysdercus fasciatus* (capsid), *Musca domestica* (housefly), *Pieris brassicae* (white butterfly), *Plutella xylostella* (diamond back moth), *Phaedon cochleariae* (mustard beetle), *Aonidiella* spp. (scale insects),
- 30 *Trialeurodes* spp. (white flies), *Bemisia tabaci* (white fly), *Blattella germanica* (cockroach), *Periplaneta americana* (cockroach), *Blatta orientalis* (cockroach) *Spodoptera littoralis* (cotton

leafworm), Heliothis virescens (tobacco budworm) Chortiocetes terminifera (locust),
Diabrotica spp. (rootworms), Agrotis spp. (cutworms), Chilo partellus (maize stem borer),
Nilaparvata lugens (planthopper), Nephotettix cincticeps (leafhopper), Panonychus ulmi
(European red mite), Panonychus citri (citrus red mite), Tetranychus urticae (two-spotted
5 spider mite), Tetranychus cinnabarinus (carmine spider mite), Phyllocoptruta oleivora (citrus
rust mite), Polyphagotarsonemus latus (broad mite) and Brevipalpus spp. (mites). Further
examples include insects which adversely affect the health of the public at large and animals.

In order to apply the compounds of formula (I) to the locus of the nematode, insect or
acarid pest, or to a plant susceptible to attack by the nematode, insect or acarid pest, the
10 compound is usually formulated into a composition which includes in addition to a
compound of formula (I) a suitable inert diluent or carrier material, and, optionally, a surface
active agent. The amount of composition generally applied for the control of nematode pests
gives a rate of active ingredient from 0.01 to 10 kg per hectare, preferably from 0.1 to 6 kg
per hectare.

15 Thus in another aspect the present invention provides a insecticidal, acaricidal or
nematicidal composition comprising an insecticidally, acaricidally or nematicidally effective
amount of a compound of formula (I) and a suitable carrier or diluent therefor.

The compositions can be applied to the soil, plant or seed, to the locus of the pests, or
to the habitat of the pests, in the form of dusting powders, wettable powders, granules (slow
20 or fast release), emulsion or suspension concentrates, liquid solutions, emulsions, seed
dressings, fogging/smoke formulations or controlled release compositions, such as
microencapsulated granules or suspensions.

Dusting powders are formulated by mixing the active ingredient with one or more
finely divided solid carriers and/or diluents, for example natural clays, kaolin, pyrophyllite,
25 bentonite, alumina, montmorillonite, kieselguhr, chalk, diatomaceous earths, calcium
phosphates, calcium and magnesium carbonates, sulphur, lime, flours, talc and other organic
and inorganic solid carriers.

Granules are formed either by absorbing the active ingredient in a porous granular
material for example pumice, attapulgite clays, Fuller's earth, kieselguhr, diatomaceous
30 earths, ground corn cobs, and the like, or on to hard core materials such as sands, silicates,
mineral carbonates, sulphates, phosphates, or the like. Agents which are commonly used to

aid in impregnation, binding or coating the solid carriers include aliphatic and aromatic petroleum solvents, alcohols, polyvinyl acetates, polyvinyl alcohols, ethers, ketones, esters, dextrins, sugars and vegetable oils. with the active ingredient. Other additives may also be included, such as emulsifying agents, wetting agents or dispersing agents.

- 5 Microencapsulated formulations (microcapsule suspensions CS) or other controlled release formulations may also be used, particularly for slow release over a period of time, and for seed treatment.

Alternatively the compositions may be in the form of liquid preparations to be used as dips, irrigation additives or sprays, which are generally aqueous dispersions or emulsions
10 of the active ingredient in the presence of one or more known wetting agents, dispersing agents or emulsifying agents (surface active agents). The compositions which are to be used in the form of aqueous dispersions or emulsions are generally supplied in the form of an emulsifiable concentrate (EC) or a suspension concentrate (SC) containing a high proportion of the active ingredient or ingredients. An EC is a homogeneous liquid composition, usually
15 containing the active ingredient dissolved in a substantially non-volatile organic solvent. An SC is a fine particle size dispersion of solid active ingredient in water. In use, the concentrates are diluted in water and applied by means of a spray to the area to be treated.

Suitable liquid solvents for ECs include methyl ketones, methyl isobutyl ketone, cyclohexanone, xylenes, toluene, chlorobenzene, paraffins, kerosene, white oil, alcohols, (for
20 example, butanol), methylnaphthalene, trimethylbenzene, trichloroethylene, N-methyl-2-pyrrolidone and tetrahydrofurfuryl alcohol (THFA).

Wetting agents, dispersing agents and emulsifying agents may be of the cationic, anionic or non-ionic type. Suitable agents of the cationic type include, for example, quaternary ammonium compounds, for example cetyltrimethyl ammonium bromide.
25 Suitable agents of the anionic type include, for example, soaps, salts of aliphatic monoesters of sulphuric acid, for example sodium lauryl sulphate, salts of sulphonated aromatic compounds, for example sodium dodecylbenzenesulphonate, sodium, calcium or ammonium lignosulphonate, or butylnaphthalene sulphonate, and a mixture of the sodium salts of diisopropyl- and triisopropylnaphthalene sulphonates. Suitable agents of the non-ionic type
30 include, for example, the condensation products of ethylene oxide with fatty alcohols such as oleyl alcohol or cetyl alcohol, or with alkyl phenols such as octyl phenol, nonyl phenol and

octyl cresol. Other non-ionic agents are the partial esters derived from long chain fatty acids and hexitol anhydrides, the condensation products of the said partial esters with ethylene oxide, and the lecithins.

These concentrates are often required to withstand storage for prolonged periods and after such storage, to be capable of dilution with water to form aqueous preparations which remain homogeneous for a sufficient time to enable them to be applied by conventional spray equipment. The concentrates may contain 10-85% by weight of the active ingredient or ingredients. When diluted to form aqueous preparations such preparations may contain varying amounts of the active ingredient depending upon the purpose for which they are to be used.

The compounds of formula (I) may also be formulated as powders (dry seed treatment DS or water dispersible powder WS) or liquids (flowable concentrate FS, liquid seed treatment LS, or microcapsule suspension CS) for use in seed treatments.

In use the compositions are applied to the insect pests, to the locus of the pests, to the habitat of the pests, or to growing plants liable to infestation by the pests, by any of the known means of applying pesticidal compositions, for example, by dusting, spraying, or incorporation of granules.

The compound of formula (I) may be the sole active ingredient of the composition or it may be admixed with one or more additional active ingredients such as insecticides, synergists, herbicides, fungicides or plant growth regulators where appropriate. Suitable additional active ingredients for inclusion in admixture with a compound of formula (I) may be compounds which will broaden the spectrum of activity of the compositions of the invention or increase their persistence in the location of the pest. They may synergise the activity of the compound of formula (I) or complement the activity for example by increasing the speed of effect or overcoming repellency. Additionally multi-component mixtures of this type may help to overcome or prevent the development of resistance to individual components. The particular additional active ingredient included will depend upon the intended utility of the mixture and the type of complementary action required. Examples of suitable insecticides include the following:

- a) Pyrethroids such as permethrin, esfenvalerate, deltamethrin, cyhalothrin in particular lambda-cyhalothrin, biphenethrin, fenpropathrin, cyfluthrin, tefluthrin, fish safe pyrethroids

for example ethofenprox, natural pyrethrin, tetramethrin, s-bioallethrin, fenfluthrin, prallethrin and 5-benzyl-3-furylmethyl-(E)-(1R,3S)-2,2-dimethyl-3-(2-oxothiolan-3-ylidenemethyl) cyclopropane carboxylate;

- b) Organophosphates such as profenofos, sulprofos, methyl parathion, azinphos-methyl, demeton-s-methyl, heptenophos, thiometon, fenamiphos, monocrotophos, profenophos, triazophos, methamidophos, dimethoate, phosphamidon, malathion, chloropyrifos, phosalone, terbufos, fensulfothion, fonofos, phorate, phoxim, pyrimiphos-methyl, pyrimiphos-ethyl, fenitrothion or diazinon;
- c) Carbamates (including aryl carbamates) such as pirimicarb, cloethocarb, carbofuran, furathiocarb, ethiofencarb, aldicarb, thiofurox, carbosulfan, bendiocarb, fenobucarb, propoxur or oxamyl;
- d) Benzoyl ureas such as triflumuron, or chlorfluazuron;
- e) Organic tin compounds such as cyhexatin, fenbutatin oxide, azocyclotin;
- f) Macrolides such as avermectins or milbemycins, for example such as abamectin, ivermectin, and milbemycin;
- g) Hormones and pheromones;
- h) Organochlorine compounds such as benzene hexachloride, DDT, chlordane or dieldrin;
- i) Amidines, such as chlordimeform or amitraz;
- j) Fumigant agents;
- k) Imidacloprid;
- l) spinosad.

In addition to the major chemical classes of insecticide listed above, other insecticides having particular targets may be employed in the mixture if appropriate for the intended utility of the mixture. For instance selective insecticides for particular crops, for example stemborer specific insecticides for use in rice such as cartap or buprofezin can be employed. Alternatively insecticides specific for particular insect species/stages for example ovo-larvicides such as chlofentezine, flubenzimine, hexythiazox and tetradifon, motilicides such as dicofol or propargite, acaricides such as bromopropylate, chlorobenzilate, or growth regulators such as hydramethylron, cyromazine, methoprene, chlorfluazuron and diflubenzuron may also be included in the compositions.

Examples of suitable synergists for use in the compositions include piperonyl butoxide, sesamax, safroxan and dodecyl imidazole.

Suitable herbicides, fungicides and plant-growth regulators for inclusion in the compositions will depend upon the intended target and the effect required.

5 An example of a rice selective herbicide which can be included is propanil, an example of a plant growth regulator for use in cotton is "Pix", and examples of fungicides for use in rice include blasticides such as blasticidin-S. The ratio of the compound of formula (I) to the other active ingredient in the composition will depend upon a number of factors including type of target, effect required from the mixture etc. However in general, the
10 additional active ingredient of the composition will be applied at about the rate at which it is usually employed, or at a slightly lower rate if synergism occurs.

The invention is illustrated by the following Examples. Examples 1-25 illustrate the preparation of a range of compounds of formula (I). Examples 26-33 illustrate compositions suitable for the application of the compounds of formula (I) according to the invention. The
15 following ingredients are referred to by their Registered Trade Marks and have the composition as shown below.

<u>Registered Trade Mark</u>	<u>Composition</u>
Synperonic NP8 } Synperonic NP13 } Synperonic OP10 }	Nonylphenol-ethylene oxide condensate
Aromasol H	Alkylbenzene solvent
Solvesso 200	Inert organic diluent
Keltrol	Polysaccharide

Throughout the Examples references to Compound Nos. refer to compounds numbered on Table I above. Selected NMR data and melting point data are presented in the
20 Examples. For NMR data, no attempt has been made to list every absorption. The following abbreviations are used throughout the Examples:

- 17 -

mp = melting point (uncorrected)

ppm = parts per million

s = singlet

t = triplet

m = multiplet

dd = double doublet

d = doublet

q = quartet

EXAMPLE 1

This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-endo-3-formyl-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 1).

Stage 1

A few drops of dilute hydrochloric acid were added to a solution of 2,5-dimethoxytetrahydrofuran (16.5g) in water (70ml). After stirring at room temperature for 30 minutes 2,2,2-trifluoroethylamine hydrochloride (16.9g), acetonedicarboxylic acid (18.3g) and sodium acetate (10.0g) were added and the mixture stirred at room temperature for 2 days. The mixture was diluted to 500ml with water, saturated with potassium carbonate and extracted with ethyl acetate (twice). The combined organic extracts were washed with aqueous potassium carbonate, dried (magnesium sulfate) and evaporated under reduced pressure. Distillation (90°C; 0.1mmHg) gave 8-(2,2,2-trifluoroethyl)-8-azabicyclo-

15 [3.2.1]octan-3-one (8.7g).

Stage 2

Potassium tert-butoxide (5.4g) was added slowly with cooling to a stirred solution of 8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octan-3-one (4.0g) and tosylmethyl isocyanide (4.9g) in 1,2-dimethoxyethane (80ml, dry) and ethanol (5ml, dry) under nitrogen at such a

20 rate so as to keep the temperature below 10°C. The mixture was stirred for 18 hours while allowing it to warm to room temperature, evaporated under reduced pressure and added to aqueous potassium carbonate solution. The mixture was extracted with ethyl acetate (twice) and the combined extracts were dried (magnesium sulfate) and evaporated under reduced pressure to give an oil. The mixture was extracted with hexane heated to 65°C and the

25 extracts allowed to cool and evaporated under reduced pressure to give exo-3-cyano-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (2.5g) mp 90-92°C.

Stage 3

exo-3-Cyano-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (1.09g) in tetrahydrofuran (10ml) was added to a stirred solution of lithium diisopropylamide [made by adding n-butyl lithium (2.4ml of a solution in hexane, 2.5M) to diisopropylamine (0.61g) in tetrahydrofuran (10ml)] at -25°C under nitrogen. After 2 hours at -25°C the mixture was cooled to -76°C and 3,5-dichloropyridine (0.74g) in tetrahydrofuran (10ml) added. The mixture was allowed to warm to room temperature, stirred for 18 hours and evaporated under reduced pressure. The mixture was dissolved in ether, washed with water (x2), dried (magnesium sulfate) and evaporated under reduced pressure. Chromatography [SiO₂; diethyl ether:hexane (20:80) to (50:50)] gave exo-3-(5-chloropyrid-3-yl)-endo-3-cyano-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (0.45g) mp 109.5-111.5°C.

Stage 4

The product from Stage 3 (4.5g) was dissolved in diethyl ether (dry;100ml), cooled to -10°C under an atmosphere of nitrogen and a solution of lithium aluminium hydride (30ml of a solution in diethyl ether, 1M) added slowly over 20 minutes to the vigorously stirred mixture, maintaining the reaction temperature at -10°C. On complete addition the reaction was stirred at -10 °C for 30 minutes, cooled to -76 °C and treated with water (30ml) over 5 minutes allowing the temperature to gradually rise to -20°C. The ether soluble fraction was decanted from the white precipitate, which was washed with further ether (100ml). The ether fractions were combined, washed with dilute aqueous sodium carbonate solution (100ml), dried (magnesium sulfate), and evaporated under reduced pressure to give an oil. The oil was fractionated by chromatography (silica; hexane:ethyl acetate, 4:1) to give the required product as a colourless solid, 2.2g, mp 100.5 -101.5°C.

¹H NMR (CDCl₃): δ 1.50(2H,m); 1.90(2H,m); 2.25(2H,dd); 2.75(2H,dd); 2.85(2H,q); 3.50(2H,broad m); 7.50(1H,t); 8.35(1H,d); 8.45(1H,d); 9.40(1H,s)ppm.

EXAMPLE 2

This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-endo-3-(2,2-dichloroethenyl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 2).

The product from Example 1, Stage 4 (2.0g) in carbon tetrachloride (dry, 50ml) containing triphenyl phosphine (8.3g) was stirred and heated to reflux under an atmosphere of nitrogen for 9hours and stored at ambient temperature for 18hours. The solvent was

evaporated under reduced pressure and the brown residue partitioned between aqueous sodium carbonate and ethyl acetate. The organic fraction was separated, dried (magnesium sulfate) and evaporated under reduced pressure. The residue was fractionated by chromatography (silica; 4:1 hexane:ethyl acetate) to give the required product as a light brown oil, 1.55g.

¹H NMR (CDCl₃): δ 1.95(4H,m); 2.25(2H,dd); 2.45(2H,dd); 2.85(2H,q); 3.40(2H, broad m); 6.50(1H,s); 7.55(1H,t); 8.40(1H,d); 8.45(1H,d)ppm.

EXAMPLE 3

This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-endo-3-ethynyl-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 3).

The product from Example 2 (0.2g) was dissolved in tetrahydrofuran (dry, 3ml) and cooled to -60°C with stirring under an atmosphere of nitrogen. A solution of n-butyl lithium (0.47ml of a solution in hexane, 2.5M) was added over 1 hour, the reaction stirred for 1 hour at -60°C and n-butanol (1ml) added. The reaction was allowed to warm to ambient temperature and dilute aqueous sodium carbonate(5.0ml) added. The mixture was extracted with ethyl acetate (2x5ml), dried (magnesium sulfate) and evaporated under reduced pressure to give a yellow oil. The oil was fractionated by chromatography (silica; hexane:ethyl acetate 4:1) to give the required product as a pale brown oil, 0.075g.

¹H NMR (CDCl₃): δ 1.90(2H,broad m); 2.20(2H,dd); 2.30(2H,dd); 2.40(1H,s); 2.50(2H,m); 2.85(2H,q); 3.40(2H,broad m); 7.85(1H,t); 8.45(1H,broad s); 8.70(1H,broad s)ppm.

EXAMPLE 4

This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-endo-3-hydroxymethyl-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 4).

exo-3-(5-Chloropyrid-3-yl)-endo-3-formyl-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (prepared as in Example 1, 0.10g) was dissolved in anhydrous diethyl ether (1ml) and stirred at 0°C under nitrogen. Lithium aluminium hydride (0.2ml of a solution in diethyl ether, 1.0M) was added dropwise over 15 minutes, the reaction stirred for a further 30 minutes at 0°C and allowed to warm to ambient temperature. After 30minutes the reaction was treated with water (5ml) and then ethyl acetate (10ml) added. The organic fraction was separated, dried (magnesium sulfate) and evaporated to give an oil which was

fractionated by preparative thick layer chromatography (silica, eluent: ethyl acetate) to give the required product, 0.054g, as a colourless oil.

^1H NMR(CDCl_3): δ 1.80(2H,m); 2.00(2H,m); 2.15(4H,m); 2.85(2H,q); 3.40(2H,m); 3.65(2H,m); 7.50(1H,dd); 8.45(1H,d); 8.50(1H,d)ppm.

5

EXAMPLE 5

This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-endo-3-(2-chloroethynyl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 5).

The product from Example 2 (0.12g) in methanol (1ml) containing sodium methoxide (0.016g) was stirred under nitrogen, heated to 60°C for 10 minutes and allowed to cool to ambient temperature for 18 hours. Further sodium methoxide (0.1g) was added and the mixture heated for 2 hours at 60°C and cooled to ambient temperature. The mixture was poured into water (5ml), extracted with ethyl acetate (5ml) and the organic fraction dried (magnesium sulfate) and evaporated under reduced pressure to give an oil which was fractionated by preparative thick layer chromatography (silica; hexane:ethyl acetate 4:1 by volume) to give the required product as a colourless solid, 0.017g, mp 74-6°C.

15

EXAMPLE 6

This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 6).

exo-3-(5-Chloropyrid-3-yl)-endo-3-cyano-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (0.2g) was dissolved in dry tetrahydrofuran (2ml) and cooled to -10°C with stirring under nitrogen. Lithium aluminium hydride (1ml of a solution in tetrahydrofuran, 1M) was slowly added over 20 minutes and the reaction allowed to warm to ambient temperature and stored for 18 hours. The reaction was cooled to 0°C, treated with water (5ml) and extracted with ethyl acetate (2x10ml). The organic fractions were combined, dried (magnesium sulfate) and evaporated under reduced pressure to give a brown oil, 0.18g, which was purified by chromatography (silica; hexane:ethyl acetate 3:1 by volume) to give the required product as a colourless solid, 0.025g, mp 104-5°C.

25

EXAMPLE 7

This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-endo-3-carboxy-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 7).

Stage 1

5 exo-3-(5-Chloropyrid-3-yl)-endo-3-cyano-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (1.7g) was dissolved in concentrated sulfuric acid (5ml) and stored for 40 hours. The mixture was poured into ice/water (100ml), basified with sodium hydroxide and extracted into ethyl acetate (200ml), dried (magnesium sulfate) and evaporated under reduced pressure. The residue was recrystallised from a small volume of ethyl acetate to give exo-3-
10 (5-chloropyrid-3-yl)-endo-3-carboxamido-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane as a colourless solid, 1.4g, mp 233-4°C.

Stage 2

The product from Stage 1 (1.2g) was finely powdered, stirred in acetonitrile (20ml) at ambient temperature and treated portionwise with nitrosonium tetrafluoroborate (1.4g). The
15 suspension gradually dissolved to give a green solution which subsequently became yellow whilst gas was evolved from the reaction mixture. The reaction was stirred for 1 hour, heated to 50°C for 5 minutes and cooled to ambient temperature. Water (2ml) was added, the solvent evaporated under reduced pressure and the residue extracted with sodium hydroxide solution. The basic, aqueous fraction was washed with ethyl acetate (2x20ml) and the
20 aqueous fraction separated, taken to pH 7 with hydrochloric acid and extracted with ethyl acetate (2x20ml). The combined organic fractions were dried (magnesium sulfate) and evaporated under reduced pressure to give the required product as a light brown solid, 0.3g, mp 160-3°C.

EXAMPLE 8

25 This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-endo-3-carbomethoxy-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 8).

The product from Example 7 (0.050g) in acetone (2ml) containing anhydrous potassium carbonate (0.1g) and methyl iodide (0.027g) were stirred at 60°C in a sealed glass vessel for 2 hours. The solvent was evaporated and the residue was fractionated by
30 preparative thick layer chromatography (silica; eluent ethyl acetate) to give the required product was obtained as a colourless solid, 0.023g, mp 104-5°C.

EXAMPLE 9

This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-endo-3-(N-hydroxyiminomethyl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 9).

The aldehyde from Example 1 (0.075g) in propan-2-ol (1ml) was treated with a
5 solution of hydroxylamine hydrochloride (0.20g) in water (2ml) and taken to pH 7 with 50% aqueous sodium hydroxide. The reaction was stirred at ambient temperature for 1h, evaporated under reduced pressure and the residue treated with aqueous sodium carbonate and extracted into ethyl acetate (2x5ml). The combined organic extracts were dried (magnesium sulfate) and evaporated under reduced pressure. The residue was fractionated
10 by thick layer chromatography (silica; ethyl acetate) to give the required product as a colourless solid, 0.052g, mp 133-5°C.

exo-3-(5-Chloropyrid-3-yl)-endo-3-(N-methoxyiminomethyl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 10), (colourless solid, mp 94-5°C), was prepared in a similar procedure using O-methyl hydroxylamine.

15

EXAMPLE 10

This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-endo-3-(2,2-dicyanoethenyl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 11).

The aldehyde from Example 1 (0.33g), malononitrile (5ml) and ammonium acetate (0.1g) were heated in a sealed glass vessel to 100°C with stirring for 1 hour under an
20 atmosphere of nitrogen. The reaction was poured into aqueous sodium carbonate solution and extracted with ethyl acetate (3x 20ml). The combined organic phase was washed with aqueous sodium carbonate solution (20ml), dried (magnesium sulfate) and evaporated under reduced pressure to give a brown oil. The oil was fractionated by preparative thick layer chromatography (silica; 40% ethyl acetate:hexane) and the oil obtained heated to 125°C at
25 1mm Hg to remove traces of malononitrile to give the required product as a brown gum, 0.080g.

¹H NMR (CDCl₃): δ 1.75(2H,m); 2.10(2H,m); 2.50(2H,dd); 2.75(2H,dd); 2.85(2H,q); 3.50(2H,broad signal); 7.60(1H,t); 7.65(1H,s); 8.40(1H,broad signal); 8.55(1H,broad signal)ppm.

EXAMPLE 11

This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-endo-3-difluoromethyl-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 12).

The aldehyde from Example 1 (0.10g) in diethylaminosulfurtrifluoride (1ml) was stirred at 35°C for 9 hours and stored at ambient temperature for 18 hours. The mixture was poured into ice/water (100ml), basified with potassium carbonate, extracted with ethyl acetate (100ml), dried (magnesium sulfate) and evaporated under reduced pressure to give an oil, 0.075g. The oil was fractionated by chromatography (silica, hexane:tert-butyl methyl ether 4:1 by volume) to give the required product (0.006g).

¹H NMR (CDCl₃): δ 1.70(2H,m); 2.10(2H,m); 2.35(4H,m); 2.85(2H,q); 3.45(2H,m); 6.00(1H,t,J=60Hz); 7.60(1H,dd); 8.40(1H,d); 8.50(1H,d)ppm.

EXAMPLE 12

This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-endo-3-trifluoromethyl-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 13).

The acid from Example 7 (0.6g) was dissolved in anhydrous hydrofluoric acid (9.6g) in a Monel 400 autoclave. Sulfur tetrafluoride (6g) was pressurised into the mixture which was gradually heated from ambient temperature to 100°C for 12 hours. The autoclave was cooled in stages to -15°C and the gases vented to waste. The residual brown solution was poured onto ice (50g), the organic material extracted with dichloromethane (3x20ml), the combined organic phase washed with water (twice), dried (magnesium sulfate) and evaporated under reduced pressure. The residue was treated with aqueous hydrochloric acid (40ml, 2M) and washed with ethyl acetate (2x20ml). The aqueous phase was basified with sodium carbonate, extracted with ethyl acetate (2x20ml), dried (magnesium sulfate) and evaporated under reduced pressure to give the required product as a brown gum, 0.25g.

¹H NMR (CDCl₃): δ 1.70(2H,m); 1.90(4H,m); 2.60(2H,q); 3.00(2H,dd); 3.45(2H,m); 7.75(1H,dd); 8.40(1H,d); 8.60(1H,d)ppm.

EXAMPLE 13

This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-endo-3-ethenyl-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 14).

Methyl triphenyl phosphonium bromide (0.71g) was suspended in dry tetrahydrofuran (10ml) and stirred under nitrogen at ambient temperature whilst a solution of lithium

bis(trimethylsilyl) amide (2.0ml of a solution in tetrahydrofuran, 1M) was slowly added. The yellow mixture was stirred for 20 minutes and the aldehyde from Example 1 (0.33g) added. The reaction was heated to 40°C for 10 minutes, treated with water (25ml) and extracted with ethyl acetate (25ml). The organic phase was separated, extracted with hydrochloric acid (2x25ml, 2M) and the organic fraction discarded. The aqueous phase was made basic with sodium carbonate, extracted with diethyl ether (2x25ml), dried (magnesium sulfate) and evaporated under reduced pressure to give the required product as an off-white solid, 0.29g, mp 78-80°C.

10 The following analogues were made using a similar procedure:-

exo-3-(5-Chloropyrid-3-yl)-endo-3-(E)-(2-cyclopropylethenyl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound no. 15), yellow oil; ¹H NMR (CDCl₃): δ 0.05(2H,m); 0.35(2H,m); 0.75(1H,m); 1.65(2H,m); 1.85(2H,m); 2.05(4H,m); 2.60(2H,q); 3.15(2H,m); 5.40(1H,t); 6.70(1H,d); 7.45(1H,broad signal); 8.15(1H,broad signal); 8.30(1H,broad signal)ppm.

(E) and (Z) (ratio 1:2)-exo-3-(5-Chloropyrid-3-yl)-endo-3-(2-methoxyethenyl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 16), oil; ¹H NMR (CDCl₃): δ 1.80-2.30(6H,m); 2.50(2H,dd); 2.85(2H,q); 3.35(2H,m); 3.50(3H,s); 4.60(Z isomer, d); 5.00(E isomer, d); 5.80(Z isomer, d); 6.30(E isomer, d); [7.50(dd); 7.60(dd); 8.35(d); 8.40(d); 8.50(d) E/Z isomers]ppm.

exo-3-(5-Chloropyrid-3-yl)-endo-3-(E)(2-chloroethenyl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 17), oil; ¹H NMR (CDCl₃): δ 1.90(4H,m); 2.10(2H,dd); 2.35(2H,dd); 2.80(2H,q); 3.40(2H,broad signal); 6.10(2H,m); 7.45(1H,t); 8.40(2H,m)ppm.

25 exo-3-(5-Chloropyrid-3-yl)-endo-3-(Z)(2-chloroethenyl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 18), colourless solid, mp 96.0-98.5°C.

Compounds 17 and 18 were separated by chromatography (silica; hexane/ethyl acetate 3:1 by volume) from a 2:1 mixture.

exo-3-(5-Chloropyrid-3-yl)-endo-3-(E)-(2-phenethenyl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 19), yellow oil; ¹H NMR (CDCl₃): δ 1.90(4H,m);

2.40(4H,m); 2.90(2H,q); 3.40(2H,broad signal); 6.35(1H,d); 6.55(1H,d); 7.20-7.35(5H,m); 7.55(1H,dd); 8.35(1H,d); 8.45(1H,d)ppm.

exo-3-(5-Chloropyrid-3-yl)-endo-3-(E)-(2-cyanoethenyl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 20), colourless solid, mp 129-133°C.

5

EXAMPLE 14

This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-endo-3-methoxymethyl-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No 21).

The alcohol from Example 4 (0.2g) was dissolved with stirring in dimethyl sulfoxide (2ml) containing powdered potassium hydroxide (1g) and methyl iodide (1ml) at ambient
10 temperature. The red-brown mixture was stirred for 1 hour, poured into water (20ml), extracted with diethyl ether (2x20ml), dried (magnesium sulfate) and evaporated under reduced pressure to give a brown oil. The oil was fractionated by thick layer chromatography (silica; ethyl acetate) to give the required product, 0.03g, as a colourless oil.

¹H NMR (CDCl₃): δ 1.80(2H,m); 2.00-2.25(6H,m); 2.85(2H,q); 3.20(3H,s);
15 3.40(4H,broad signal); 7.50(1H,t); 8.40(2H,dd)ppm.

EXAMPLE 15

This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-endo-3-(2-(pyrid-3-yl)ethynyl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 22).

The alkyne from Example 3 (0.38g), 3-bromopyridine (0.5g), tetrakis(triphenyl-
20 phosphine) palladium (0) (0.05g, catalyst), copper bromide (0.05g, catalyst), in triethylamine (1ml) were stirred at 40°C under an atmosphere of nitrogen for 30 minutes. The mixture was evaporated under reduced pressure, extracted with ethyl acetate (50ml) and washed with sodium carbonate solution. The organic phase was extracted with hydrochloric acid (2x25ml, 2M) and the aqueous phase separated. The aqueous phase was washed with
25 ethyl acetate (2x25ml), basified with sodium carbonate solution and the aqueous phase re-extracted with ethyl acetate (2x50ml). The combined organic phase extracts were dried (magnesium sulfate) and evaporated under reduced pressure to give a yellow oil which was fractionated by preparative thick layer chromatography (silica; ethyl acetate) to give the required product as an off-white solid, 0.10g, mp 115.0-119.5°C.

- 26 -

¹H NMR (CDCl₃): δ 2.00(2H,m); 2.30(4H,m); 2.50(2H,m); 2.90(2H,m); 3.50(2H,m); 7.20(1H,dd); 7.70(1H,double triplet); 7.80(1H,t); 8.50(1H,d); 8.55(1H,dd); 8.70(1H,d); 8.80(1H,d)ppm.

5 The following analogues were prepared using a similar procedure:-

exo-3-(5-Chloropyrid-3-yl)-endo-3-(2-(4-fluorophenyl)ethynyl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No 23), brown solid, mp 96-101°C.

¹H NMR (CDCl₃): δ 2.00(2H,m); 2.30(4H,m); 2.60(2H,m); 2.90(2H,q); 3.50(2H,m); 7.00(2H,m); 7.40(2H,m); 7.85(1H,dd); 8.45(1H,d); 8.80(1H,d)ppm.

10 exo-3-(5-Chloropyrid-3-yl)-endo-3-(2-(pyrid-2-yl)ethynyl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 24), brown solid, mp 110-114°C.

EXAMPLE 16

This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-endo-3-pivaloyloxymethyl-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 25).

The alcohol from Example 4 (0.2g) was dissolved in dichloromethane (dry; 8ml) and treated with pivaloyl chloride (0.086ml) and N,N-diisopropylethylamine (0.12ml) at ambient temperature. The mixture was stirred for 22hours, heated to reflux for 6hours and allowed to cool to ambient temperature for 18hours. The reaction was treated with water (50ml) and extracted with ethyl acetate (50ml). The mixture was acidified with hydrochloric acid (50ml, 2M) and the acidic fraction collected. The organic phase was further treated with hydrochloric acid (50ml, 2M) and the aqueous, acidic fractions combined and washed with ethyl acetate. The aqueous fraction was separated, basified with sodium hydrogen carbonate solution and extracted with ethyl acetate (2x50ml). The organic phase extracts were combined, dried (magnesium sulfate) and evaporated under reduced pressure to give a brown oil which solidified on cooling. The solid was washed with a small volume of 20% diethyl ether in hexane to give the required product as an off-white solid, 0.13g, mp 155-157°C.

EXAMPLE 17

This Example illustrates the preparation of exo-3-(3,5-difluorophenyl)-endo-3-(N-acetylaminomethyl)-8-(methyl)-8-azabicyclo[3.2.1]octane (Compound No. 26).

Stage 1

- 5 Potassium tert-butoxide (22.4g) was added portionwise to a stirred mixture of tropinone (11.58g) and tosylmethyl isocyanide (21.2g) in dry 1,2-dimethoxyethane (240ml) and ethanol (8ml) at 0°C under an atmosphere of nitrogen at such a rate to maintain the reaction temperature between 0°C and 10°C. The mixture was allowed to warm to room temperature and stirred for a further 4 hours. After standing the mixture at room temperature for 3 days it
10 was filtered and the solid residue washed with 1,2-dimethoxyethane. The filtrate was evaporated under reduced pressure and fractionated by chromatography [silica, 10% methanol in dichloromethane) to give exo-3-cyano-8-methyl-8-azabicyclo[3.2.1]octane (9.1g).

Stage 2

- exo-3-Cyano-8-methyl-8-azabicyclo[3.2.1]octane (13.6 g) in dry tetrahydrofuran
15 (80ml) was added dropwise to a stirred solution of lithium diisopropylamide [made by adding n-butyl lithium (40ml of a solution in hexane, 2.5M) to diisopropylamine (14.0ml) in tetrahydrofuran (80ml)] at -25°C under an atmosphere of nitrogen. The mixture was stirred at -25°C for 0.5 hours and cooled to -78°C. 1,3,5-Trifluorobenzene (12.0g) in tetrahydrofuran (80ml) was added dropwise at such a rate to maintain the temperature below -65°C. The
20 mixture was allowed to warm to room temperature overnight and then poured into water and extracted with dichloromethane. The combined extracts were washed with brine, dried (MgSO₄) and evaporated under reduced pressure to give a yellow solid. This was recrystallised from diethyl ether to give exo-3-(3,5-difluorophenyl)-endo-3-cyano-8-methyl-8-azabicyclo[3.2.1]octane. The mother liquor from the recrystallisation was chromatographed
25 [silica, 10% methanol in dichloromethane] to give further desired product, giving a total yield of 11.2g.

Stage 3

- The product from Stage 2 (2.5g) in dry diethyl ether (15ml) was stirred at 0°C under an atmosphere of nitrogen, lithium aluminium hydride (15.3ml of a diethyl ether solution,
30 1.0M) was added dropwise and the reaction was stirred for a further 30 minutes. The reaction was allowed to warm to ambient temperature and stored for 18hours. The mixture

was re-cooled to 0°C, quenched with a mixture of methanol/water/acetic acid (8:2:1), stirred for 1.5 hours, diluted with aqueous sodium chloride solution and made basic with aqueous sodium hydroxide (2M). The mixture was extracted with dichloromethane, dried (magnesium sulfate) and evaporated under reduced pressure and the residue fractionated by chromatography (silica, dichloromethane:methanol) to give exo-3-(3,5-difluorophenyl)-endo-3-aminomethyl-8-methyl-8-azabicyclo[3.2.1]octane, 1.9g, mp 113-7°C (Compound No. 27).

Stage 4

The product from Stage 3 (0.5g) was dissolved in dry diethyl ether (10ml) containing dry triethylamine (0.26ml) at 0°C with stirring and treated with acetyl chloride (0.15g). The reaction was stirred at 0°C for 1 hour, allowed to warm to ambient temperature and the mixture extracted with dichloromethane. The extract was washed with aqueous sodium chloride solution, water, dried (magnesium sulfate) and evaporated under reduced pressure to give the required product as a yellow solid, 0.35g, mp 56.5-57.2°C.

exo-3-(3,5-Difluorophenyl)-endo-3-(N-benzoylaminomethyl)-8-methyl-8-azabicyclo[3.2.1]octane (Compound No. 28), colourless solid, mp 149.3°C, was prepared in a similar way using benzoyl chloride.

EXAMPLE 18

This Example illustrates the preparation of exo-3-(3,5-difluorophenyl)-endo-3-carbomethoxyamino-8-methyl-8-azabicyclo[3.2.1]octane (Compound No. 29).

The carboxamide from Example 7, Stage 1 (0.56g) was dissolved in methanol (10ml) containing sodium methoxide (0.325g) at ambient temperature with stirring. Bromine (0.11ml) was added to the solution and the mixture stirred for 2 hours. The solvent was evaporated under reduced pressure and the residue extracted with diethyl ether (200ml). The organic phase was washed with water, dried (magnesium sulfate) and evaporated under reduced pressure to leave a residue. The residue was fractionated by chromatography (silica, 20% methanol in dichloromethane) to give the required product, 0.16g, mp 120-2°C.

EXAMPLE 19

This Example illustrates the preparation of exo-3-(pyrid-3-yl)-endo-3-methoxy-8-methyl-8-azabicyclo[3.2.1]octane (Compound No. 30).

Stage 1

5 2-Chloro-5-aminopyridine (15.0g) was dissolved in concentrated hydrochloric acid (150ml) at 0°C with stirring. Sodium nitrite (10.47g) in water (5ml) was added dropwise maintaining the reaction below 5°C. Sodium iodide (26.23g) in water (20ml) was slowly added to the orange solution at 0-5°C and stirred for 1 hour and allowed to warm to ambient temperature over 18 hours. The reaction was diluted with water (300ml), the solid which had
10 formed filtered from solution and dissolved in ethyl acetate. The organic phase was washed with dilute aqueous sodium hydroxide, aqueous sodium hydrogen carbonate, dried (magnesium sulfate) and evaporated under reduced pressure. The residue was fractionated by chromatography (silica hexane/ 5-10% ethyl acetate) to give 2-chloro-5-iodopyridine, 14.9g, as a colourless solid, mp 89-90°C.

15 Stage 2

N-Carboethoxytropinone (1.0g) was dissolved with stirring in dry chloroform (2.5ml), cooled to 0°C under an atmosphere of nitrogen and treated with trimethylsilyl iodide (1.22g). The mixture was heated to reflux for 5 hours, stored at ambient temperature for 2 days and re-cooled to 0°C under an atmosphere of nitrogen with stirring. The reaction was
20 treated dropwise with a solution of hydrogen chloride in methanol (2.0ml, 5M), stirred for 1.5 hours and evaporated under reduced pressure. The brown solid obtained was treated with toluene and the resulting mixture evaporated under reduced pressure. The residual solid was suspended in dry dichloromethane (5ml), cooled to 0°C under an atmosphere of nitrogen and a solution of pyridine (1.0g) and 4-N,N-dimethylaminopyridine (5mg, catalyst) in
25 dichloromethane (5ml) added. The solution was stirred for 0.5 hour, di-tert-butyl dicarbonate (1.43g) added dropwise and the reaction allowed to warm to ambient temperature. The mixture was treated with water, extracted with dichloromethane and the combined organic phase washed with aqueous copper sulfate, water and aqueous sodium chloride, dried (magnesium sulfate) and evaporated under reduced pressure. The brown oil obtained was
30 fractionated by chromatography (silica, 30%ethyl acetate/hexane) to give N-carbo-tert-butoxy-tropinone as a pale yellow solid, 0.91g, mp 65.0-66.5°C.

Stage 3

2-Chloro-5-iodopyridine (0.32g) was dissolved in a 2:1 mixture of diethyl ether and tetrahydrofuran (12ml), cooled to -78°C under an atmosphere of nitrogen with stirring and treated dropwise with n-butyl lithium (0.53ml of a solution in hexane, 2.5M). The deep red solution was stirred at -78°C for 20 minutes, and N-carbo-tert-butoxy-tropinone (0.30g) in diethyl ether (3ml) was added dropwise, after which the reaction mixture was allowed to warm to ambient temperature slowly over 18 hours. Saturated, aqueous ammonium chloride solution was added and the mixture extracted (3 times) with ethyl acetate. The combined organic phase was dried (magnesium sulfate) and evaporated under reduced pressure to give a gum which was fractionated by chromatography (silica, hexane:ethyl acetate, 1:1) to give exo-3-(6-chloropyrid-3-yl)-endo-3-hydroxy-8-(N-carbo-tert-butoxy)-8-azabicyclo[3.2.1]-octane (Compound No. 43) as a yellow, foamy solid, 0.24g.

¹H NMR (CDCl₃): δ 1.45(9H,s); 1.75-1.95(2H,m); 1.95-2.10(2H,m); 2.10-2.50(5H,m); 4.2-4.4(2H,m); 7.25(1H,d); 7.65(1H,dd); 8.40(1H,d)ppm.

Stage 4

The product from Stage 3 (0.10g) was added to a suspension of sodium hydride (0.015g) in dry tetrahydrofuran (5ml) at 0°C under an atmosphere of nitrogen, stirred for 1 hour and methyl iodide (0.046g) was added. The reaction was stirred for 2 hours, further methyl iodide (0.02ml) added and the reaction stored at ambient temperature for 2 days. The mixture was treated with water, extracted with ethyl acetate (3 times), the combined organic phase was washed with saturated sodium chloride solution, dried (magnesium sulfate) and evaporated under reduced pressure to give an oil. The residue was fractionated by chromatography (silica; 25% ethyl acetate in hexane) to give exo-3-(6-chloropyrid-3-yl)-endo-3-methoxy-8-(N-carbo-tert-butoxy)-8-azabicyclo[3.2.1]octane (Compound No. 31), 0.056g, yellow oil.

¹H NMR (CDCl₃): δ 1.45(9H,s); 1.90-2.25(8H,m); 4.20(1H,m); 4.35(1H,m); 3.0(3H,s); 7.30(1H,d); 7.60(1H,dd); 8.35(1H,d)ppm.

Stage 5

The product from Stage 4 (0.174g) was dissolved in methanol (3.5ml) containing potassium hydroxide (0.028g) and 5% palladium on charcoal (0.174g, catalyst) added. The mixture was stirred under an atmosphere of hydrogen for 18 hours, after which time the

required hydrogenolysis was complete. The mixture was filtered, the filtrate evaporated under reduced pressure and the residue extracted into ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried (magnesium sulfate) and evaporated under reduced pressure to give exo-3-(pyrid-3-yl)-endo-3-methoxy-8-(N-carbo-tert-butoxy)-8-azabicyclo[3.2.1]octane (Compound No. 33), oil, 0.125g.

¹H NMR (CDCl₃): δ 1.40(9H,s); 1.90-2.35(8H,m); 3.0(3H,s); 4.25(1H,m); 4.35(1H,m); 7.25(1H,dd); 7.65(1H,double triplet); 8.60(1H,broad signal)ppm.

Stage 6

The product from Stage 5 (0.11g) was dissolved in formic acid (3.5ml), heated to reflux for 1 hour and cooled to ambient temperature. The mixture was treated with paraformaldehyde (0.12g) and heated to reflux with stirring for 2 hours and stored at ambient temperature for 2 days. The reaction was evaporated under reduced pressure and the residue partitioned between dichloromethane and aqueous sodium hydroxide solution. The phases were separated, the aqueous phase was re-extracted with dichloromethane and the combined organic phase was dried (magnesium sulfate) and evaporated under reduced pressure to give exo-3-(pyrid-3-yl)-endo-3-methoxy-8-methyl-8-azabicyclo[3.2.1]octane as a yellow oil, 0.073g.

¹H NMR (CDCl₃): δ 2.0-2.35(8H,m); 2.40(3H,s); 2.95(3H,s); 3.30(2H,m); 7.30(1H,dd); 7.70(1H,double triplet); 8.50(1H,dd); 8.65(1H,d)ppm.

20

In a similar procedure to Example 19, Stage 6 exo-3-(6-chloropyrid-3-yl)-endo-3-methoxy-8-(N-carbo-tert-butoxy)-8-azabicyclo[3.2.1]octane was converted to exo-3-(6-chloropyrid-3-yl)-endo-3-methoxy-8-methyl-8-azabicyclo[3.2.1]octane, (Compound No. 32), yellow oil; ¹H NMR (CDCl₃): δ 1.95-2.15(8H,m); 2.35(3H,s); 2.95(3H,s); 3.25(2H,m); 7.30(1H,d); 7.65(1H,dd); 8.40(1H,d)ppm.

25

EXAMPLE 20

This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-endo-3-(tetrazol-5-yl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 34).

exo-3-(5-Chloropyrid-3-yl)-endo-3-cyano-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (prepared in Example 1 stage 3, 0.50g) was dissolved in dry N,N-dimethylformamide (5.0ml) containing sodium azide (0.13g) and ammonium chloride (0.05g, catalyst) with

30

stirring and heated to 110°C in a sealed glass vessel for 43 hours. The mixture was evaporated under reduced pressure and the residue treated with an aqueous solution of ammonium chloride, extracted with ethyl acetate (2x10ml), dried (magnesium sulfate) and evaporated under reduced pressure to give a colourless gum. The gum was fractionated by preparative thick layer chromatography (silica; diethyl ether) to give the required product as a colourless solid, 0.13g, mp 221-222°C(dec).

¹H NMR (CDCl₃): δ 1.25(4H,m); 1.75(1H,m); 2.10(2H,d); 2.85(2H,q); 3.25(2H,d); 3.45(2H,m); 7.80(1H,m); 8.25(1H,m); 8.40(1H,m)ppm. Molecular ion 372.

EXAMPLE 21

This Example illustrates the preparation of exo-3-(5-chloropyrid-3-yl)-endo-3-(5-methyl-1,2,4-oxadiazol-3-yl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 35).

Stage 1

exo-3-(5-Chloropyrid-3-yl)-endo-3-cyano-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (prepared in Example 1 stage 3, 0.10g) was added to a mixture of hydroxylamine hydrochloride (0.15g) and potassium tert-butoxide (0.28g) in tert-butanol (2ml) with stirring under an atmosphere of nitrogen. The mixture was heated to 90-100°C for 20 hours, the mixture cooled, evaporated under reduced pressure and the residue treated with aqueous ammonium chloride. The product was extracted into ethyl acetate (2x10ml), dried (magnesium sulfate) and evaporated under reduced pressure to give a colourless oil. The oil was fractionated by preparative thick layer chromatography (silica; diethyl ether) to give endo-3-(3-amidoximido)-exo-3-(5-chloropyrid-3-yl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane (Compound No. 36) as a colourless foamy solid, (0.050g), mp 167-169°C.

Stage 2

The product from Stage 1 (0.050g) was dissolved in toluene (dry, 2ml) containing acetic anhydride (0.018g) with stirring. The mixture was heated to 80°C for 0.5 hour, then at 110°C for 11 hours. The mixture was evaporated under reduced pressure and the residue fractionated by preparative thick layer chromatography (silica; diethyl ether) to give the title product as a colourless solid, 0.026g, mp 106-108°C.

¹H NMR (CDCl₃): δ 1.50(2H,q); 1.75(2H,m); 2.40(2H,dd); 2.55(3H,s); 2.85(2H,q); 3.15(2H,dd); 3.40(2H,m); 7.35(1H,t); 8.40(1H, m); 8.50(1H, m)ppm.

EXAMPLE 22

This Example illustrates the preparation of endo-3-amino-8-(carboethoxy)-exo-3-(5-chloropyrid-3-yl)-8-azabicyclo[3.2.1]octane (Compound No. 37).

Stage 1

8-(Carboethoxy)-exo-3-(5-chloropyrid-3-yl)-endo-3-cyano-8-azabicyclo[3.2.1]octane (prepared, for example, as in WO 96/37494, 6.6g) was dissolved in concentrated sulfuric acid (40ml) containing water (10ml) and stirred at 50°C for 24hours. Further concentrated
10 sulfuric acid (20ml) was added and the mixture heated for an additional 7hours at 50°C. The reaction mixture was poured into water (500ml), basified with aqueous sodium hydroxide and the product extracted with ethyl acetate (200ml) and tert-butyl methyl ether (200ml). The extracts were combined, dried (magnesium sulfate) and evaporated under reduced pressure to give endo-8-(carboethoxy)-3-carboxamido-exo-3-(5-chloropyrid-3-yl)-8-
15 azabicyclo[3.2.1]octane (Compound No. 38) as a colourless solid (2.65g). A sample was recrystallised from ethyl acetate to give a colourless solid, mp 220.0-222.5°C.

Stage 2

The product from Stage 1 (0.10g) was added to a solution of lithium hydroxide (0.072g) in water (2ml) and 1,4-dioxane (2ml) and the mixture stirred at 40°C. Bromine
20 (0.096g) was added to the mixture in one portion and the reaction stirred for 1hour at 40°C. The volatiles were evaporated under reduced pressure and the yellow residue extracted into ethanol (5ml). The ethanolic solution was evaporated under reduced pressure to give a yellow semi-solid, which was extracted with hot ethyl acetate (10ml). The extracts were evaporated under reduced pressure to give a yellow oil. The oil was fractionated by
25 preparative thick layer chromatography (silica; ethyl acetate) to give the title product as a pale yellow oil, 0.036g.

¹H NMR (CDCl₃): δ 1.30(3H,t); 1.80(2H,d); 1.95-2.15(2H,m); 2.20-2.45(4H,m); 4.20(2H,q); 4.30(2H,m); 7.55(1H,t); 8.40(1H,d); 8.50(1H,d)ppm.

EXAMPLE 23

This Example illustrates the preparation of 8-(carboethoxy)-exo-3-(5-chloropyrid-3-yl)-endo-3-N-formylamino-8-azabicyclo[3.2.1]octane (Compound No. 39).

endo-3-Amino-8-(carboethoxy)-exo-3-(5-chloropyrid-3-yl)-8-azabicyclo[3.2.1]
5 octane (1.00g) and formic acid (10ml, 98%) were stirred and heated to reflux for 5 hours. The excess formic acid was evaporated under reduced pressure, the residue was treated with toluene (2x50ml), each time evaporating under reduced pressure to remove residual formic acid. The residue was fractionated by eluting through a column of silica with ethyl acetate followed by preparative thick layer chromatography (basic alumina; ethyl acetate) to give the
10 required product as a colourless solid, 0.19g, mp 186.5-188.5°C.

¹H NMR (CDCl₃): δ 1.30(3H,t); 2.0-2.80(8H,m); 4.15(2H,q); 4.45 (2H,m); 6.75(1H,m); 7.65(1H,t); 8.15(1H,m); 8.50(1H,d); 8.40(1H,d)ppm.

EXAMPLE 24

This Example illustrates the preparation of 8-(carboethoxy)-exo-3-(5-chloropyrid-3-yl)-endo-3-isocyano-8-azabicyclo[3.2.1]octane (Compound No. 40).
15

8-(Carboethoxy)-exo-3-(5-chloropyrid-3-yl)-endo-3-N-formylamino-8-azabicyclo[3.2.1]octane (0.15g) was dissolved in dry dichloromethane (10ml,) containing triethylamine (0.5ml) and the stirred mixture was cooled to 0°C. Phosphorus oxychloride (0.5ml) was added dropwise and the reaction stirred at 0°C for 3 hours. The mixture was then evaporated
20 under reduced pressure. The residue was treated with an aqueous solution of sodium bicarbonate and the product extracted into ethyl acetate (2x10ml), the organic extracts were combined, dried (magnesium sulfate) and evaporated under reduced pressure to give a brown gum. The gum was fractionated by preparative thick layer chromatography (silica; ethyl acetate) to give the required product, 0.12g, colourless gum.

25 ¹H NMR (CDCl₃): δ 1.30(3H,t); 2.10-2.50(8H,m); 4.20(2H,q); 4.50(2H,m); 7.75(1H,t); 8.55(2H,t)ppm.

EXAMPLE 25

This Example illustrates the preparation of 8-(carboethoxy)-exo-3-(5-chloropyrid-3-yl)-endo-3-nitro-8-azabicyclo[3.2.1]octane (Compound No. 41).

Stage 1

5 Acetonitrile (90ml) containing water (9ml) was stirred in a glass reaction vessel, cooled to -10°C and purged with nitrogen. Fluorine diluted with nitrogen was slowly bubbled into the mixture, at a rate of 5ml of fluorine per minute, for 0.5hour and sodium fluoride (5.0g) added to the solution. The mixture was stirred for 10 minutes at -5°C, cooled to -15°C and endo-3-amino-8-carboethoxy-exo-3-(5-chloropyrid-3-yl)-8-azabicyclo[3.2.1]-
10 octane (0.5g) in dichloromethane (8ml) was added and the mixture stirred for 10minutes. The reaction mixture was poured into water (500ml), basified with sodium hydrogen carbonate and extracted with dichloromethane (3x20ml). The extracts were combined, washed with water, dried (magnesium sulfate) and evaporated under reduced pressure. The residue was fractionated by preparative thick layer chromatography (silica; 10% methanol by
15 volume in ethyl acetate) to give 8-(carboethoxy)-exo-3-(5-chloropyrid-3-yl-1-oxide)-endo-3-nitro-8-azabicyclo[3.2.1]octane (Compound No. 42) as a colourless solid, 0.11g, mp 217°C (dec).

¹H NMR (CDCl₃): δ 1.25(3H,t); 1.70(2H,m); 2.00(2H,m); 2.40(2H,m); 3.45(2H,d); 4.15(2H,m); 4.45(2H,m); 7.30(1H,t); 8.20(1H,d); 8.25(1H,d)ppm.

20 Stage 2

The product from Stage 1 (0.050g) was dissolved in chloroform (2ml) with stirring and phosphorus trichloride (0.2ml) was added. The mixture was heated to 60°C in a sealed glass vessel for 2hours, cooled to ambient temperature and extracted with chloroform (5ml). The extract was treated with a solution of aqueous sodium carbonate, the organic phase
25 separated, dried (magnesium sulfate) and evaporated under reduced pressure to give the title product, 0.039g, oil.

¹H NMR (CDCl₃): δ 1.25(3H,t); 1.70(2H,m); 2.00(2H,m); 2.45(2H,m); 3.55(2H,m); 4.15(2H,q); 4.45(2H,m); 7.70(1H,t); 8.45(1H,m); 8.50(1H,m)ppm. Molecular ion 339.

EXAMPLE 26

This Example illustrates an emulsifiable concentrate composition which is readily convertible by dilution with water into a liquid preparation suitable for spraying purposes.

The concentrate has the following composition:

	% Weight
Compound No. 1	25.5
SYNPERONIC NP13	2.5
Calcium dodecylbenzenesulphonate	2.5
AROMASOL H	70

5

EXAMPLE 27

This Example illustrates a wettable powder composition which is readily convertible by dilution with water into a liquid preparation suitable for spraying purposes. The wettable powder has the following composition:

	% Weight
Compound No. 13	25.0
Silica	25.0
Sodium lignosulphonate	5.0
Sodium lauryl sulphate	2.0
Kaolinite	43.0

10

EXAMPLE 28

This Example illustrates a dusting powder which may be applied directly to plants or other surfaces and comprises 1% by weight of Compound No. 25 and 99% by weight of talc.

EXAMPLE 29

15 This Example illustrates a concentrated liquid formulation suitable for application by ultra low volume techniques after mixing with paraffinic diluents.

	% Weight
Compound No. 29	90.0
SOLVESSO 200	10.0

EXAMPLE 30

This Example illustrates a capsule suspension concentrate which is readily convertible by dilution with water to form a preparation suitable for application as an aqueous spray.

	% Weight
Compound No. 43	10.0
Alkylbenzene solvent (e.g. AROMASOL H)	5.0
Toluene di-isocyanate	3.0
Ethylenediamine	2.0
Polyvinyl alcohol	2.0
Bentonite	1.5
Polysaccharide (e.g. KELTROL)	0.1
Water	76.4

5

EXAMPLE 31

A ready for use granular formulation:

	% Weight
Compound No. 4	0.5
SOLVESSO 200	0.2
nonylphenol ethoxylate (eg Synperonic NP8)	0.1
Calcium carbonate granules (0.3-0.7 mm)	99.2

EXAMPLE 32

10 An aqueous suspension concentrate:

- 38 -

	% Weight
Compound No. 8	5.0
Kaolinite	15.0
Sodium lignosulphonate	3.0
nonylphenolethoxylate (eg Synperonic NP 8)	1.5
propylene glycol	10.0
Bentonite	2.0
Polysaccharide (eg Keltrol)	0.1
Bactericide (eg Proxel; Proxel is a registered Trade Mark)	0.1
Water	63.3

EXAMPLE 33

This Example illustrates a water dispersible granule formulation.

	% Weight
Compound No. 20	5
Silica	5
Sodium lignosulphate	10
Sodium dioctylsulphosuccinate	5
Sodium acetate	10
Montmorillonite powder	65

5

EXAMPLE 34


This Example illustrates the insecticidal properties of the compounds of formula (I). The activity of the compounds of formula (I) was determined using a variety of pests. The pests were treated with a liquid composition containing 500 parts per million (ppm) by weight of the compound unless otherwise stated. The compositions were made by dissolving the compound in acetone and ethanol (50:50) mixture and diluting the solutions with water containing 0.05% by weight of a wetting agent sold under the trade name "SYNPERONIC" NP8 until the liquid composition contained the required concentration of the compound. "SYNPERONIC" is a Registered Trade Mark.

10


The test procedure adopted with regard to each pest was basically the same and comprised supporting a number of the pests on a medium which was usually a substrate, a host plant or a foodstuff on which the pests feed, and treating either or both the medium and the pests with the compositions. The mortality of the pests was then assessed at periods
5 usually varying from two to five days after the treatment.

The results of the tests against peach aphid (Myzus persicae) are presented below. The results indicate a grading of mortality (score) designated as A, B or C wherein C indicates less than 40% mortality, B indicates 40-79% mortality and A indicates 80-100% mortality; "-" indicates that either the compound was not tested or no meaningful result was
10 obtained. In this test Chinese cabbage leaves were infested with aphids, the infested leaves were sprayed with the test composition, and the mortality assessed after 3 days. Compound Nos. 1, 2, 3, 5, 6, 8, 9, 10, 11, 12, 14, 15, 16, 17, 18, 19, 20, 21, 23, 24, 28, 37 and 40 gave a mortality score of A.


In addition, in a similar test against red spider mites (Tetranychus urticae)
15 Compounds Nos. 2, 3, 5, 8, 14, 16, 18, 21, 26, 28, 33 and 40 gave a mortality score of A.

Chemical Formulae Used in the Description


(I)




(II)




(III)




(IV)




(V)




(VI)




(VII)




(VIII)




(IX)



(X)




(XI)



(XII)

CLAIMS

1. A compound of formula (I):



- 5 wherein Ar is optionally substituted phenyl or optionally substituted 5- or 6-membered heterocyclic ring containing from 1 to 3 heteroatoms individually selected from nitrogen, oxygen and sulfur atoms, and at least one unsaturation (double bond) between adjacent atoms in the ring, said heterocyclic ring being optionally fused to a benzene ring, wherein the substituents, if present, are selected from halogen atoms, cyano, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkenyl, alkylthio and alkyl
- 10 amino groups; R represents hydrogen or cyano or a group selected from alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, aralkenyl, alkynyl, alkoxycarbonyl, alkanesulfonyl, arenesulfonyl, alkenyloxycarbonyl, aralkyloxycarbonyl, aryloxycarbonyl, heterocyclalkyl, carbamyl, dithiocarboxyl or XR^3 (where X represents oxygen or a group NR^4), provided that when R is alkenyl, aralkenyl or alkynyl said group does not have an unsaturated carbon atom bonding directly to the ring nitrogen of formula (I); R^3 and R^4 are, independently, hydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, aralkenyl, alkynyl, heterocyclalkyl, alkoxycarbonyl or carboxylic acyl; alkyl moieties of R, R^3 and R^4 comprise from 1 to
- 15 15 carbon atoms, and are optionally substituted with one or more substituents selected from halogen, cyano, carboxyl, carboxylic acyl, carbamyl, alkoxycarbonyl, alkoxy, alkylendioxy, hydroxy, nitro, amino, acylamino, imidate and phosphonate groups; aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, aralkenyl, alkynyl, alkoxycarbonyl, alkanesulfonyl, arenesulfonyl, alkenyloxycarbonyl, aralkyloxycarbonyl, aryloxycarbonyl, heterocyclalkyl, carbamyl or dithiocarboxyl moieties of R, R^3 and R^4 comprise from 1 to 15 carbon atoms, and are optionally substituted with one or more substituents selected from, halogen, cyano, carboxyl, carboxylic acyl, carbamyl,
- 20 25

alkoxycarbonyl, alkoxy, alkylendioxy, hydroxy, nitro, haloalkyl, alkyl, amino, acylamino, imidate and phosphonato groups; R¹ represents hydrogen, hydroxy, alkyl, alkoxy, amino, nitro, isocyanato, acylamino, hydroxyalkyl, optionally substituted heteroaryl, alkoxyalkyl, haloalkyl, halohydroxyalkyl, aralkyloxyalkyl, acyloxyalkyl, amidoximido, sulfonyloxyalkyl, aminoalkyl, alkoxycarbonylamino, acylaminoalkyl, cyanoalkyl, imino, formyl, acyl or carboxylic acid or an ester or amide thereof, or alkenyl or alkynyl either of which is optionally substituted by halogen, alkoxy, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl or cyano; or an acid addition salt, quaternary ammonium salt or N-oxide derived therefrom.

10

2. A compound of formula (I) as claimed in claim 1 wherein Ar is phenyl, pyridinyl, pyridazinyl or pyrazinyl, all being optionally substituted with halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₂₋₄ alkynyl or cyano.

15

3. A compound of formula (I) as claimed in claim 1 or 2 wherein R is C₁₋₄ alkyl, C₂₋₄ haloalkyl (the α -carbon being unsubstituted) or C₁₋₄ alkoxycarbonyl.

20

4. A compound of formula (I) as claimed in claim 1, 2 or 3 wherein R¹ is C₂₋₄ alkenyl or C₂₋₄ alkynyl either of which is optionally substituted by halogen, alkoxy, cycloalkyl, phenyl (optionally substituted by halogen), pyridinyl (optionally substituted by halogen) or cyano.

25

5. An insecticidal, acaricidal or nematocidal composition comprising an insecticidally, acaricidally or nematocidally effective amount of a compound of formula (I) and a suitable carrier or diluent therefor.


30

6. A method of combating and controlling insect, acarine or nematode pests at a locus which comprises treating the pests or the locus of the pests with an effective amount of a compound according to claim 1 or a composition according to claim 5.

7. A method according to claim 6 wherein the pests are insect pests of growing plants.

8. A method of preparing a compound of formula (I) which comprises:


(a) converting the cyano of a compound of formula (II):



5

into an R¹ group;


(b) replacing the cyano of a compound of formula (II):



with an R¹ group;

(c) to form a compound of formula (I) wherein R¹ is hydroxy, reacting a compound of formula (VIII):

10



with a product obtainable by treating a compound of formula ArHal (wherein Hal is a halogen) with a suitable lithium species.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 97/02986

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D451/02 C07D451/04 C07D451/06 A01N43/90

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	BELL M.R. & ARCHER S.: "Ethyl 3.alpha.-phenyltropane-3.beta.-carboxylate and related compounds" THE JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 82, no. 7-9, July 1960, pages 4638-4641, XP002053360 see compounds V,VI,VII,X,XII,XIII,XV and XVI, page 4638 see compounds XX and XXI, page 4639 --- -/--	1-3

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

2 February 1998

Date of mailing of the international search report

13. 02. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hartrampf, G

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/GB 97/02986

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CIGNARELLA G. ET AL.: "A new synthesis of tropane derivatives" THE JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 83, no. 10-12, October 1961, pages 4999-5003, XP002053361 see compounds I, II and III, page 4999 see compounds IX,X,XI,XII,XIII,XIV,XV,XVI and XVII, page 5000 ---	1,2
X	US 3 120 537 A (ARCHER S. & BELL R.) 4 February 1964 see claims 1-20 ---	1-3
X	US 3 133 073 A (ARCHER S.) 12 May 1964 see claims 1,3,4 ---	1,2
X	US 3 546 232 A (KAISER C. & ZIRKLE C.L.) 8 December 1970 see claims 1-4 ---	1,2
X	DE 21 43 587 A (A.H. ROBINS CO., INC.) 9 March 1972 see claims 1-9 ---	1,2
X	DAUM S.J. ET AL.: "Analgesic activity of the epimeric tropane analogs of meperidine. A physical and pharmacological study" JOURNAL OF MEDICINAL CHEMISTRY, vol. 18, no. 5, May 1975, pages 496-501, XP002053362 see compounds 1,3,9-13 and 15-19, page 497 ---	1,2
X	DE 27 49 584 A (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH) 18 May 1978 see claims 1,2,5,9,10,12,13; examples 1,10 ---	1,2
X	US 4 180 669 A (WINN M.) 25 December 1979 see example XXIV ---	1,2
X	GUTKOWSKA B. ET AL.: "syntezy niektórych pochodnych 8-alkilo-8-aza-bicyklo[3.2.1]oktan-3-onu" ACTA POLONIAE PHARMACEUTICA, vol. 38, no. 4, 1981, pages 411-415, XP002053363 see compound IV, page 411 ---	1
X	EP 0 053 744 A (C.H. BOEHRINGER SOHN) 16 June 1982 see claims 1-3 ---	1,2

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 97/02986

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 122 580 A (F. HOFFMANN-LA ROCHE & CO., AKTIENGESELLSCHAFT) 24 October 1984 see claims 1-3,5-7,9,12; examples 1,2,5,12-14 ---	1
X	FR 2 548 666 A (DELALANDE SA) 11 January 1985 see claims 1-3; examples 1,4 ---	1
X	MAAG H. ET AL.: "94. 5-(N-Arylnortropan-3-yl)- and 5-(N-arylpiperidin-4-yl)-2,4-diamino- pyrimidines. Novel inhibitors of dihydrofolate reductase" HELVETICA CHIMICA ACTA, vol. 69, no. 4, April 1986, pages 887-897, XP002053364 see compounds 2, 3, 9, 10, 12 and 13, page 891 ---	1
X	EP 0 315 390 A (BEECHAM GROUP PLC) 10 May 1989 see claims 1-4,7-9; examples 1-4,10-12 ---	1
X	EP 0 398 578 A (PFIZER INC.) 22 November 1990 see claims 1-4,11 ---	1,2
X	WO 91 17156 A (PFIZER INC) 14 November 1991 see claims 1,30-32 ---	1,2
X	EP 0 498 331 A (HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED) 12 August 1992 see claim 11 see examples 1d,1e,2d,2e,7a,7b,10a, 10b,12a,12b,13a,13b ---	1
X	EP 0 518 805 A (H. LUNDBECK A/S) 16 December 1992 see claim 7 ---	1,2
X	WO 93 00313 A (VIRGINIA COMMONWEALTH UNIVERSITY) 7 January 1993 see claims 58,59 ---	1,2
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 97/02986

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	REPKE D.B. ET AL.: "Abbreviated ibogaine congeners. Synthesis and reactions of tropan-3-yl-2- and -3-indoles. Investigation of an unusual isomerization of 2-substituted indoles using computational and spectroscopic techniques" JOURNAL OF ORGANIC CHEMISTRY, vol. 59, no. 8, 22 April 1994, pages 2164-2171, XP002023167 see compounds 2a,3a,4a,5a, scheme 1, page 2165 see page 2169, column 2 - page 2170, column 1 ---	1
X	US 5 491 148 A (BERGER J. & CLARK R.D.) 13 February 1996 see claims 1,2; example 2 ---	1
P,X	WO 97 13770 A (NEUROSEARCH A/S) 17 April 1997 see claim 11; example 1 ---	1,2
Y	WO 93 14636 A (DOWELANCO) 5 August 1993 see the whole document ---	1-8
Y	WO 95 03306 A (E.I. DU PONT DE NEMOURS AND COMPANY) 2 February 1995 see the whole document ---	1-8
Y	WO 96 08968 A (DOWELANCO) 28 March 1996 see the whole document ---	1-8
P,Y	WO 96 37494 A (ZENECA LIMITED) 28 November 1996 cited in the application see the whole document ---	1-8
E	WO 97 43286 A (ZENECA LIMITED) 20 November 1997 see the whole document -----	1-8

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 97/02986

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 3120537 A	04-02-64	NONE	
US 3133073 A	12-05-64	NONE	
US 3546232 A	08-12-70	US 3657252 A	18-04-72
DE 2143587 A	09-03-72	AU 459212 B	20-03-75
		AU 3271771 A	01-03-73
		CA 941379 A	05-02-74
		CH 552588 A	15-08-74
		FR 2103642 A	14-04-72
		GB 1304649 A	24-01-73
		US 3657257 A	18-04-72
		ZA 7105770 A	26-04-72
DE 2749584 A	18-05-78	LU 76173 A	10-07-78
US 4180669 A	25-12-79	NONE	
EP 53744 A	16-06-82	DE 3045688 A	08-07-82
		AR 227450 A	29-10-82
		AU 7822281 A	10-06-82
		CA 1143734 A	29-03-83
		CS 228526 B	14-05-84
		DK 536381 A	05-06-82
		GB 2088869 A,B	16-06-82
		JP 57120588 A	27-07-82
		US 4393069 A	12-07-83
EP 122580 A	24-10-84	AU 567731 B	03-12-87
		AU 2664284 A	18-10-84
		CA 1244028 A	01-11-88
		DE 3466988 A	03-12-87
		DK 169984 A	15-10-84
		US 4774249 A	27-09-88
		US 4590270 A	20-05-86
		JP 59199685 A	12-11-84
FR 2548666 A	11-01-85	NONE	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 97/02986

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 315390 A	10-05-89	AT 108791 T	15-08-94
		DE 3850742 D	25-08-94
		DE 3850742 T	27-10-94
		JP 1157978 A	21-06-89
		US 4959367 A	25-09-90

EP 398578 A	22-11-90	WO 9014087 A	29-11-90
		AT 150021 T	15-03-97
		AU 618191 B	12-12-91
		AU 5512590 A	22-11-90
		CA 2016860 A	17-11-90
		CN 1032209 B	03-07-96
		CN 1047291 A	28-11-90
		DE 69030134 D	17-04-97
		DE 69030134 T	19-06-97
		ES 2098248 T	01-05-97
		IL 94357 A	04-08-96
		IL 114174 A	18-06-96
		JP 2001886 C	20-12-95
		JP 3005478 A	11-01-91
		JP 7035368 B	19-04-95
		NO 180268 B	09-12-96
		PL 163580 B	29-04-94
		PT 94045 B	31-12-96
		WO 9014088 A	29-11-90
		US 5338754 A	16-08-94
		US 5391742 A	21-02-95
		US 5185343 A	09-02-93
		US 5272160 A	21-12-93
		RU 2029769 C	27-02-95

WO 9117156 A	14-11-91	AU 642994 B	04-11-93
		AU 7456591 A	27-11-91
		CN 1056497 A	27-11-91
		CS 9101354 A	13-05-92
		EG 19647 A	30-08-95
		EP 0554247 A	11-08-93
		IL 98056 A	27-11-95
		JP 6099423 B	07-12-94
		NO 301979 B	05-01-98

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 97/02986

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9117156 A		PL 169267 B RU 2068414 C US 5306723 A	28-06-96 27-10-96 26-04-94
EP 498331 A	12-08-92	AT 138377 T AU 641842 B AU 1060592 A CA 2060573 A CS 9200297 A DE 69210849 D DE 69210849 T ES 2089255 T IE 74905 B IL 100861 A JP 2118750 C JP 5059049 A JP 8009613 B MX 9200471 A NO 300040 B NZ 241481 A PL 169092 B RU 2075479 C US 5340936 A US 5334599 A US 5234931 A	15-06-96 30-09-93 06-08-92 05-08-92 12-08-92 27-06-96 05-12-96 01-10-96 13-08-97 18-02-97 06-12-96 09-03-93 31-01-96 01-08-92 24-03-97 27-06-94 31-05-96 20-03-97 23-08-94 02-08-94 10-08-93
EP 518805 A	16-12-92	AU 664557 B AU 1984892 A CZ 9302726 A WO 9222554 A EP 0593511 A HU 9500094 A JP 6508360 T MX 9205117 A NO 934494 A NZ 243065 A SK 140993 A US 5665725 A	23-11-95 12-01-93 13-04-94 23-12-92 27-04-94 29-05-95 22-09-94 01-08-93 11-02-94 26-07-95 09-11-94 09-09-97
WO 9300313 A	07-01-93	AU 676993 B	10-04-97

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 97/02986

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9300313 A		AU 2294592 A CA 2111957 A EP 0591426 A JP 6509069 T ZA 9204775 A	25-01-93 07-01-93 13-04-94 13-10-94 16-04-93
US 5491148 A	13-02-96	NONE	
WO 9713770 A	17-04-97	AU 7291796 A	30-04-97
WO 9314636 A	05-08-93	US 5244906 A AU 651516 B AU 3239693 A BR 9205804 A CA 2105556 A EP 0577788 A JP 6509359 T	14-09-93 21-07-94 01-09-93 17-05-94 24-07-93 12-01-94 20-10-94
WO 9503306 A	02-02-95	AU 7474794 A	20-02-95
WO 9608968 A	28-03-96	US 5393767 A AU 7800394 A	28-02-95 09-04-96
WO 9637494 A	28-11-96	AU 5698896 A GB 2301819 A	11-12-96 18-12-96
WO 9743286 A	20-11-97	NONE	